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Abstract 
Neuropeptidomics refers to a global characterization approach for the investigation of 
neuropeptides, often under specific physiological conditions. Neuropeptides comprise a complex 
set of cell-to-cell signaling molecules that are important in regulatory functions and behavior in 
the nervous system. Neuropeptide production typically involves endoproteolytic prohormone 
cleavage, exoproteolytic cleavage, and post-translational modifications by a variety of enzymes. 
Neuropeptides are packaged into and eventually released from the large dense-core vesicles in a 
regulated secretory pathway.  
Neuropeptidomics is inherently challenging because neuropeptides are spatially, 
temporally and chemically heterogeneous in the brain. In addition, the unconventional peptide 
precursor cleavages and various post-translational modifications require the unbiased 
measurements of actual peptide forms. Mass spectrometry (MS), coupled with optimized liquid 
chromatography separation and aided by appropriate sample preparation, has been successfully 
applied for peptide identification and quantitation.  
Neuropeptide production regulated by DIMM-dependent genetic mechanism and post-
translational processing through -amidation has been studied with different MS-based 
approaches such as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS 
and electrospray ionization ion-trap (ESI-IT) MS. DIMM, a transcription factor in Drosophila, 
appears able to make non-peptidergic cells into peptidergic neurons. Qualitative MS approaches 
allowed us to observe the fully processed ectopic peptide MII in Drosophila non-peptidergic 
cells only when DIMM was present. Quantitative MS approaches, together with molecular 
biological methods, revealed DIMM enabled this complete and efficient ectopic peptide 
processing through regulating gene CG13248. In addition, an important post-translational 
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modification, peptide -amidation, was studied with mice of different genotypes on different 
copper diets. The results on the peptide level changes of mature peptides and their immature 
intermediate forms facilitate our understanding on peptide amidation reaction and its dedicated 
enzyme peptidylglycine -amidating monooxygenase (PAM). 
Neurons and glia are two main types of cells in the central nervous system. Analogous to 
neuropeptidome, the knowledge of the gliopeptidome would aid our understanding of the 
interaction between glia and neurons. Therefore, the peptides in and regulatedly released from 
glia were examined. Peptides derived from proteins or putatively from neuropeptide precursors 
were identified with liquid chromatography coupled to mass spectrometry (LC-MS). Future 
studies would focus on the confirmation of the putatively identified peptides and the functions of 
identified peptides in glia.  
This dissertation demonstrates MS-based approaches are useful tools for probing peptides 
qualitatively and quantitatively, which would greatly expand our understanding of cell-to-cell 
communication in the nervous system. 
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Chapter 1. Neuropeptidomics:                                                                  
Introduction and Dissertation Overview 
Introduction was adapted from Yin, P; Hou, X.; Romanova, E.V.; Sweedler, J.V. in 
Neuropeptides: Methods and Protocol. Humana press, submitted (Invited review). Copyright © 
Humana press. 
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1.1 Notes and Acknowledgments 
This chapter starts with introduction to neuropeptidomics, which is adapted from a 
portion of an invited review article entitled “Neuropeptidomics: Mass spectrometry-based 
qualitative and quantitative analysis” that will be published in a book entitled “Neuropeptides: 
Methods and Protocol” by Humana press, co-authored with Xiaowen Hou, Elena V. Romanova, 
and Jonathan V. Sweedler. I’d like to acknowledge the co-authors’ contributions to the review 
manuscript and Stephanie C. Barker’s final editing of the manuscript. The chapter continues with 
the introduction of three mass spectrometric techniques and a brief overview on MS-based 
peptide characterization approaches, and ends with the dissertation overview. The material is 
based upon work supported by the National Science Foundation (NSF) under Award No. CHE-
0526692, by Award No. NS031609 from the National Institute of Neurological Disorders and 
Stroke (NINDS), and by Award No. DA018310 from the National Institute on Drug Abuse 
(NIDA).  
1.2 Introduction 
Neuropeptides comprise a complex set of signaling molecules that are involved in 
regulatory functions and behavioral control, such as feeding, sleeping, and learning. 
Neuropeptidomics refers to a global characterization approach for the investigation of 
neuropeptides in cells and tissue in the nervous system, often under specific physiological 
conditions. Neuropeptidomics is inherently challenging because neuropeptides are spatially, 
temporally and chemically heterogeneous, and are intrinsically in low relative abundance. In 
addition, the variations inherent to neuropeptide prohormone processing and the presence of 
post-translational modifications (PTMs) make neuropeptides difficult to predict in silico from 
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genomic information. Therefore, neuropeptidomics methodologies generally demand high 
sensitivity, great selectivity and a wide dynamic range of detection.
1-7
 
Although there are several methods for targeted peptide studies, mass spectrometry (MS), 
with its qualitative and quantitative capabilities, is quickly becoming a leading technique in 
neuropeptidomics. Aided by the development of enhanced sample preparation techniques and 
high performance liquid chromatography (HPLC), MS provides fast, sensitive, accurate, and 
high-throughput peptidomic analyses of neuropeptides in complex biological samples without 
requiring prior knowledge of the peptide sequences.
7-9
 Since its early success in characterizing 
thyrotropin-releasing hormone,
10
 MS has been used to characterize hundreds of putative 
signaling peptides in a wide range of animals from invertebrates to vertebrates.
11-19
 In addition, 
several MS-based measurement approaches have been developed that enable relative quantitation 
of peptide levels in biological samples, including correlating peptide level changes to specific 
traits, conditions and even behavior.
20-22
 
By implementing the appropriate sample preparation protocols and LC-MS platforms, 
MS-based neuropeptidomics analysis can provide a wealth of information about the cells/tissue 
under investigation: identification and characterization,
23-26
 distribution and location,
27,28
 
temporal and spatial release dynamics,
29
 and relative level changes.
20-22,30-32
 This dissertation 
explores extraction-based strategies in peptide identification and quantitation with different LC-
MS platforms. Scrupulous sampling, optimized HPLC separation, and appropriate MS detection 
are essential to successful neuropeptidomics analyses. Sampling is emphasized because the 
detection of neuropeptides in complex biological matrices can be compromised by the presence 
of salts, lipids and numerous protein degradation products. General protocol steps include the 
mechanical disruption of cells or tissue by homogenization, extraction of peptides with organic 
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solvents and/or acids, desalting and pre-concentration, and direct MS analysis or HPLC 
fractionation followed by MS-based peptide measurement, sequencing, and identification (Figure 
1.1). 
There are two major approaches to MS-based quantitative analysis of peptides. One is 
stable isotopic labeling, and the other is label-free quantitation (Figure 1.2). During the labeling 
quantitation (Figure 1.2.A), neuropeptides from experimental and control samples are chemically 
modified with the addition of structurally identical functional groups that incorporate different 
isotopes of the same element; thus, after labeling, neuropeptides from the control and sample 
treatments are distinguished by mass, and the relative change in peak heights between these 
conditions are obtained for each peptide pair. Common isotopic reagents target the N-terminus 
and the -amino group of Lys (e.g., d0 or d6 acetic anhydride, d0 or d4 succinic anhydride,21 and 
d0- or d9-trimethylammoniumbutyrate),
30,31
 or the C-terminus (e.g., d0- or d3-methanol).
33
 This 
dissertation elaborates on a labeling protocol that uses the commercially available reagent 
succinic anhydride for peptide quantitation (see Chapter 3) because it produces stable labeling 
products with measurable mass differences between light and heavy forms (although other 
reagents are available
9,30-32
). In contrast, label-free quantitation aims to correlate the mass 
spectrometric signals of peptides with the peptide abundance by running the samples in parallel 
without introducing the label reagents (Figure 1.2.B). Therefore, it does not limit the number of 
samples to be compared. However, label-free quantitation usually requires high reproducibility 
from sampling to LC-MS analysis and has normalization involved before the comparison.
34-37
 A 
tandem MS-based approach was developed to quantify an ectopic peptide in low level (see 
Chapter 2) as well as LC-MS-based quantitative analysis to study the -amidation reaction in 
mouse pituitary (see Chapter 4). 
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Although there are a number of MS-based techniques available, the primary MS 
platforms described in this dissertation include direct matrix-assisted laser/desorption ionization 
time-of-flight mass spectrometry (MALDI-TOF MS), electrospray ionization ion-trap mass 
spectrometry (ESI-IT MS), and electrospray ionization quadrupole time-of-flight mass 
spectrometry (ESI-Qq-TOF MS), all of which could be coupled with either nano-scale HPLC or 
capillary HPLC. This chapter reviews these three MS instrumentation platforms and MS-based 
peptide characterization approaches. The specific utilization of these techniques in peptide 
sequencing and quantitation will be discussed throughout the dissertation. 
1.3 Introduction to Mass Spectrometers for Peptide Characterization 
Mass spectrometry is a technique to characterize a variety of molecules by detecting their 
molecular masses and structures. The rapid growth in applications of mass spectrometry for 
biological macromolecules occurred with the introduction of soft ionization techniques, namely 
electrospray ionization (ESI)
38
 and matrix-assisted laser desorption/ionization (MALDI).
39-41
 
This breakthrough was emphasized by the Nobel Prize in Chemistry of 2002 awarded to John 
Fenn and Koichi Tanaka. Since then, mass spectrometry has been experiencing notable 
development and become a leading technique in characterizing proteins and peptides in a 
spectrum of fields such as biology,
42,43
 neuroscience,
24,44
 and pharmacology.
45-48
 
Mass spectrometry is the study of gas-phase ions, and a mass spectrometer generally 
includes an ion source, a mass analyzer, and a detector, all of which are under a series of vacuum 
systems. In ESI-based MS, the sample is typically dissolved into an appropriate solution, 
introduced through a direct infusion with a syringe pump or via elution from a liquid 
chromatography separation, and then ionized to produce the gas-phase ions for analysis. In 
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MALDI-based MS, the sample is mixed with a solution of a UV-absorbing compound as 
“matrix”, and spotted on a metal plate to be co-crystalized. Once shot with a laser, the sample is 
ionized by the assistance of matrix and the produced ions are carried into the gas phase. The 
mass analyzer measures the mass-to-charge ratios (m/z) of the gas-phase ions derived from 
analytes, and the detector produces a cascade of electrons multiplied from the ions incident upon 
it. The vacuum system maintains low pressures (10
-3
 to 10
-7
 mtorr) to provide an environment 
with minimum undesirable interference to the ion path and a pressure gradient to guide the ions 
in the instrument. Eventually, the electric signals generated at the detector are transferred to the 
data analysis computer. 
Various combinations of ionization methods and mass analyzers exist for different 
platforms of mass spectrometers.
49
 In this dissertation, I primarily employed three widely used 
platforms to investigate the peptide sequencing and functional studies. They are matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF MS), electrospray 
ionization quadrupole time-of-flight mass spectrometer (ESI-Qq-TOF MS), and electrospray 
ionization ion-trap mass spectrometer (ESI-IT MS). I will discuss the three types of instruments 
in terms of their basic working principles and widespread applications in peptide characterization. 
1.3.1 Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass 
Spectrometry (MALDI-TOF MS) 
Matrix-Assisted Laser Desorption/Ionization (MALDI) was first described by Michael 
Karas and Franz Hillenkamp in the 1980s,
39,40
 and developed to characterize biological 
macromolecules by Koichi Tanaka.
41
 For this ionization, the analyte is co-crystalized with UV-
absorbing matrix, typically a small organic compound such as 2,5-dihydroxybenzoic acid (DHB), 
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-cyano-4-hydroxycinnamic acid (-CHCA), or sinapinic acid (SA) according to different 
molecular weights of analytes, on a metal (gold or steel) plate (Figure 1.3). As illustrated in 
Figure 1.4, once the crystallized surface is exposed to a short wavelength laser pulse, the matrix 
molecules is vaporized, and the embedded analytes are also carried into the gas phase. Due to the 
acidity of most matrix molecules and the dissolving solutions for analytes, the ionization 
generally occurs by protonation. In the gas phase, the protonated ions having mass-to-charge 
ratios (m/z) acquire the kinetic energy (EK) by being accelerated in an electric field with a 
potential of V, and then enter a field-free region with a length of L, where the ions travel to the 
detector in certain time (t) at a rate (ν):  
   
 
 ⁄   
    ⁄  (  ⁄ )
     
According to: 
   ⁄ (    ⁄ )   
The mass-to-charge ratio (m/z) is related to the flight time (t) for a fixed voltage (V) and flight 
path (L). 
One of the challenges for MALDI-TOF MS to accurately measure m/z is the energy 
spread of the analyte ions during ionization. Ions of the same mass may not be desorbed and 
ionized at the same time and location. The slightly different flight times results in broadening the 
peak width, and thus reducing the resolving power. Pulse ion extraction
50
 and reflectron 
configuration
51
 have been widely used to improve the MALDI-TOF MS resolution. The former 
one cancels out the energy spread by delaying the ion extraction at the source, and the later one 
compensates the fight time differences by reflecting the analytes back to the detector with 
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electrostatic ion mirrors (Figure 1.4.B). In Chapter 4 of this dissertation, linear and reflectron 
modes are used to study the peptide stability.  
MALDI-TOF MS is a very sensitive technique with detection limit down to amol-fmol of 
peptides. It is also tolerant to some contaminants at a certain amount (e.g. urea at 0.5 M, glycerol 
at 1%, and alkali metal cations at 0.5 M).
52
 Therefore, MALDI can be used to directly measure 
the peptides in single cells
53-55
 and to study the peptide locations in intact tissue slices
56-59
 with 
less sample preparation. Nevertheless, appropriate sample preparations are often applied for 
better sensitivity, higher mass accuracy and resolution.
60,61
 The nature of MALDI-TOF MS also 
renders it the capability to analyze the same sample multiple times, to provide simple peptide 
profiles with singly charged ions, and to study the molecules in a wide mass range from ~600 Da 
to ~100,000 Da.
62
 MALDI-TOF MS is also very useful for screening the samples for checking 
the success of sample preparation and gathering guidance information prior to other analyses. In 
addition, as shown in Figure 1.5, offline coupling high performance liquid chromatography to 
MALDI-TOF MS provides even more sensitive detection of peptides. LC-MALDI has been 
shown to detect a complimentary set of peptides to LC-ESI.
63
 Throughout the dissertation, both 
direct MALDI and LC-MALDI are employed for peptide measurements and/or quantitation. 
1.3.2 Electrospray Ionization Quadrupole Time-of-Flight Mass Spectrometry (ESI-
Qq-TOF MS) 
Another soft ionization approach is electrospray ionization (ESI), which can also 
interface with time-of-flight analyzer. Most peptide analysis is performed in acidic solution with 
positive mode of ESI. In one of the most popular theories of ESI, the acidic solution is sprayed 
with assistance of nebulizer (typically N2) through a conductive needle maintained at a high 
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voltage. The spray produces a Taylor cone from which droplets of analyte solutions are emitted. 
Multiply charged peptide droplets move toward the instrument under guidance of voltage and 
vacuum gradients, during which a flow of dry gas (typically N2) assists the evaporation of the 
solvent from droplets until the force of the Coulomb repulsion exceeds the surface tension of the 
droplets. The droplet explodes into smaller charged droplets, and the smaller doplets repeat this 
cycle until gaseous protonated ions are formed (Figure 1.6).  
A more sensitive version of ESI is the nano-electrospray ion source which is suitable for 
measurements of microliter samples at low flow rates of 20-500 nL/min. The analyte solution in 
a few microliters is sprayed out of a capiliary with a fine tip (i.d. 5-30 m) to produce much 
smaller droplets, which help evaporate the solvent of the droplets, and thus improves ionization 
efficiency by up to 500-fold.
64-66
 This source is readily coupled with nanoLC separation, 
providing a great amount of information on small volume but complicated biological samples. 
Several factors could be considered to optimize ionization in ESI. For example, the spray 
needle should be in good condition (e.g. not being clogged or broken) and well positioned. Too 
long a distance between the needle and the pinhole of the cap decreases the signal, while too 
short a distance increases the risk of arcing and damaging the needle during adjustment. A 
suggested distance ranges from 0.5 mm to 2.5 mm for our on-line nano-ESI-Qq-TOF MS (maXis 
UHR-TOF MS) for stable signals. Also, shorter distances need lower capillary voltage to lead the 
analyte ions toward the pinhole, while longer distances need higher capillary voltage. In addition, 
acidic solution helps the protonated the peptides in advance of entering the MS. 
Quadrupole, as the name implies, consists of four rods arranged as two sets of two 
electrically connected rods. It guides and focuses ions by applying a combination of 
radiofrequency (RF) and direct-current (DC) voltages onto each pair of rods. A widely used 
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quadrupole instrument is a “triple quadrupole” MS, which performs an MS scan with the first 
quadrupole, fragments the isolated ions in the collision cell of the second multipole, and analyzes 
the fragment ions in the third quadrupole. When hybridized with a TOF analyser, Qq-TOF 
becomes a more popular technique for identifying and quantifying peptides.
11,21,67
 In Qq-TOF, a 
quadrupole or octopole is used to focus the ions first, a quadrupole to filter the masses of interest, 
another quadrupole to act as a collision cell for tandem MS function. The ions are then 
transferred into the TOF analyser as described above (Figure 1.7).  
ESI-Qq-TOF has been widely used as a high-throughput and accurate technique to 
identify and quantify peptides since ESI can be conveniently coupled to liquid chromatography 
separation and Qq-TOF provides high mass accuracy and resolving power.
11,21,67
 The ultra-high-
resolution TOF MS presented in the following chapters provides mass accuracy up to sub-ppm 
and resolution of 40-60K. As discussed in Chapter 6, accurate masses play an important role in 
MS-based peptide identification, and it is especially true for small peptides (M.W. < 1000 Da). 
In addition, ESI-Qq-TOF contributes much to a good volume of quantitation work due to its high 
resolving power.
20,21,31
  
1.3.3 Electrospray Ionization Ion-Trap Mass Spectrometry (ESI-IT MS) 
Another analyzer widely interfaced with ESI source is ion trap, in which ions were 
analyzed through trapping, gating, and ejecting out of the trap. As shown in Figure 1.8, 
protonated ions are introduced into the trap through capillary, skimmer, quadrupole or octopoles, 
and other lens. The ion trap includes two end caps and one ring electrode. An oscillating 
potential defined as primary radiofrequency (RF) is applied on the ring electrode, creating a 
potential wall to trap the ions. Specifying the RF manipulates the movement of ions in the trap. 
The kinetic energy of the ions in the trap is also reduced by the collision with helium buffer gas. 
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For the ESI-IT instrument utilized in multiple studies in this dissertation (HCTultra PTM 
Discovery System by Bruker Daltonics, Bremen, Germany), an auxiliary RF (1/3 of primary RF) 
is applied to the end cap at the detector side to increase the sensitivity. Ramping the primary and 
auxiliary RFs with increasing amplitude eject the ions with increasing mass-to-charge ratios 
towards the detector whenever the ions come into resonance.   
One challenge for ion trap analyzer is the space charging effects, which are caused by 
overfilling the trap with too many ions, and result in poor mass accuracy and resolution. This 
effect can be overcome by limiting the number of ions or the ion accumulation time. HCTultra 
employs Smart Ion Charge Control, reducing the risk of overloading the trap with several 
dominant peaks and allowing selection of significantly higher target values. The smart target 
number is generally set as 200,000, and the maximum accumulation time is 200 ms through all 
the studies with ESI-IT MS in this dissertation. 
Although the mass resolution of ESI-IT MS is not as good as that seen in ESI-Qq-TOF 
MS, ESI-IT MS has been widely applied to measure and sequence peptides with high sensitivity. 
The high sensitivity is attributed to the facts that (1) the compact size of the analyzer allows 
efficient transmission of ions from ion source to detector and (2) almost all the ions are 
eventually detected. In addition, the capability of ESI-IT MS to perform multiple stages of 
fragmentation helps the investigation of molecular structure and even stability (see Chapter 4). 
Coupled to different scales of HPLC, ESI-IT MS is a high-throughput technique in studying 
peptides.
18
 More details on the application of ESI-IT MS and its tandem MS will be described in 
the following chapters. 
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1.4 MS-based Peptide Characterization 
Extraction-based strategies are advanced with neuropeptide-rich samples by pooling 
many cells or tissue, although direct tissue profiling or molecular ion imaging from tissue 
sections using MALDI-based MS is prevalent to provide peptide profiles of individual organs, 
cell clusters, or even single cells with minimal sample preparation.
7
 However, larger samples do 
not always ensure analysis success. Post-mortem degradation is a critical issue in extraction-
based neuropeptidomics. In addition, some peptides are highly concentrated and localized into a 
small region within tissue.
68
 Pooling tissue may dilute those peptides in complex matrices. This 
section will briefly overview MS-based peptide characterization approaches aided by the 
development of sample preparation and liquid chromatography separation. 
1.4.1 Sample Preparation 
To detect neuropeptides normally present in vivo, multiple procedures have been 
developed.
69
 Peptidases can rapidly degrade neuropeptides, resulting in shorten forms of peptides 
different from those in live animals. At the same time, proteases cause degradation of proteins in 
higher abundance, interfering with detection of naturally formed peptides. Analysis of dialysate 
collected from live animals has been used to avoid the post-mortem issue. However, this method 
is limited by relatively low efficiency for peptide collection.
70,71
 Direct analysis of synaptosomes 
or even dense core vesicles is another option,
72
 but it involves even more complicated sample 
isolation and preparation on those subcellular compartments. Many more sample preparation 
protocols have been developed. For example, protease activity is found to be reduced by 
sacrificing animals with focused microwave irradiation,
3
 by microwaving the samples 
immediately after the dissection,
32
 by boiling the tissue immediately after the decapitation or 
cryostat dissection,
18,73
 or by using a strong, acidified organic solution for extraction.
24,74
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With minimized post-mortem degradation, extraction protocols have been optimized for 
reproducible peptide recovery. High organic and acidic solutions (e.g. acidified acetone or 
acidified methanol) are generally used for peptide extraction because the mixed solvents work 
better for peptides with different hydrophobicity. Several protocols have been compared for 
extracting peptides from mammalian tissue, and the extraction method with hot water followed 
by cold acid (e.g. acetic acid or hydrochloric acid) was reported to result in a higher reproducible 
recovery of neuropeptides.
73,75
 Recently, an extraction protocol with saturated DHB solution has 
been successfully applied to both invertebrate and vertebrate samples.
76
 The advantage of this 
protocol is technical simplicity and reproducibility, although an efficient protocol to remove 
DHB for further ESI-based MS analysis is needed to increase the analysis throughput. In 
addition, the urea solution has also been utilized for mammalian peptide identification.
77
 
Different extraction solutions have their own advantages, therefore, a multistage extraction 
protocol using boiling water and two acidic extraction solutions were used to identify peptides in 
isolated supraoptic nucleus punches from hypothalamic slices.
18
 
The raw extracts generally go through more sampling processes before the MS-based 
analysis. For example, the high organic and acidic extraction solution is usually dried in a 
vacuum concentrator, and the extracts are re-constituted with an acidic aqueous solution. C18 
cartridges, spin columns, or Ziptips can be used to desalt and pre-concentrate the samples.
18,21,24
 
A protein cut-off filter is sometimes used to remove proteins from the extracts.
18,72
 In addition, 
sample loss and artifact introduction should be avoided in each sampling step. 
1.4.2 Liquid Chromatography Separation 
The peptide extracts are usually subject to LC separation prior to MS analysis due to the 
chemical complexity and wide dynamic range of peptides in the biological samples. Capillary-
14 
 
based reversed phase (RP) LC is the most common liquid chromatographic approach to separate 
peptides in the low abundance among complex matrices.
78
 Typically, a capillary LC column (e.g., 
300-m inner diameter) or a nano LC column (e.g. 75-m inner diameter) is connected to a 
wide-bore trap column for sample loading and desalting via a column-switching device.
79
 During 
the RP-LC separation, peptides physically interact with the mobile phase and the stationary 
phase, and spend different time being eluted out with the mobile phase due to different peptide 
affinity to each phase. A changing aqueous/organic percentage of mobile phase (e.g. from 
aqueous to organic solvents) is usually programmed as a gradient to speed up and improve the 
LC separation. Acetonitrile (ACN) and methanol (MeOH) are common organic solvent for the 
mobile phase. MeOH is a weaker solvent with a lower eluotropic value than ACN for C18. 
Therefore, a higher percentage of MeOH is required to elute peptides than ACN, which is good 
for subsequent ESI MS analysis. However, MeOH aqueous solution has high viscosity, resulting 
in a higher pressure in a LC system than ACN aqueous solution.
80
 In addition, diluted acids are 
often added as ion-pairing additives in the mobile phase. The common ones include formic acid 
(FA), acetic acid (AA), trifluoroacetic acid (TFA), heptafluorobutyric acid (HFBA), and 
perfluorinated acids (PFA). Although TFA is widely used in LC and MALDI-based MS, its 
concentration has to be remained low enough (e.g. 0.01%) to avoid the ion suppression effect 
within ESI-based MS.
81
 
To increase peak capacity and resolution, multidimensional HPLC separations have been 
applied in the separation of complex samples.
81-84
 Different separation schemes such as strong 
cation-exchange (SCX),
85-87
 hydrophilic interaction chromatography (HILIC),
88,89
 affinity 
chromatography (AFC),
90
 and size exclusion chromatography (SEC)
91-93
 can be coupled to RP to 
enhanced the peptide coverage. The fractions from the 1
st
 dimensional separation are either 
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eluted stepwise to the RP column on an online setup or collected and re-injected into a RP 
column on an offline setup. In each means, the fractions are further resolved by RP-LC prior to 
MS detection. Two same separation schemes can also be coupled (e.g. RP-RP-LC), where 
different mobile phases (e.g. ACN and MeOH) or different pH conditions have been used to 
enhance the detection of peptides in low abundance.
73,94
 
As discussed earlier in MS section, LC can be coupled to MS either online or offline. 
Online coupled LC-ESI MS have been applied to identify numerous peptides in a wide range of 
animal models.
11,12,14-18,85
 Offline coupled LC-MALDI MS is a more sensitive approach,
37
 and 
has been shown to detect a complimentary set of peptides to LC-ESI.
63
 In addition, offline 
coupling allows the independent optimizations of LC and MS, and enables repeated MS analysis 
after the fractions are deposited on the MALDI target. 
1.4.3 Peptide Identification with Tandem MS 
Following LC separation, peptide ions are detected with MS scan, and peptide 
identification is generally accomplished with tandem MS analysis. Below will illustrate using 
tandem MS for peptide identification with synthetic peptides as examples.   
Introduction. A peptide is a chain of covalently linked amino acids formed by the 
condensation reaction between the amine of one amino acid and the carboxylic acid of an 
adjacent one. Therefore, a peptide has a free amine group at the N-terminus, a free carboxylic 
acid group at the C-terminus, and multiple amide bonds in between (Figure 1.9). Different 
peptides could consist of the same sets of amino acids in different orders; as a result, peptide 
identification usually requires both molecular mass matches and peptide sequencing. Edman 
degradation was traditionally used to determine the amino acid sequence of peptides or 
proteins.
95
 During the Edman reaction, a reagent (e.g. phenylisothiocyanate or PITC) was added 
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to remove the N-terminal amino acids one by one. Although Edman degradation still contributes 
to protein/peptide sequencing today, it has been widely replaced by mass spectrometry (MS) 
based approaches because Edman reaction requires long cycle time and pure individual 
proteins/peptides, and it is incapable of sequencing proteins/peptides with their N-terminus 
blocked. 
MS has become a leading information-rich technique in peptide sequencing due to its 
capability to measure the peptide masses and fragment peptides for the knowledge of both amino 
acid composition and order. The fragment ions with N-terminus are usually named a-, b- and c-
ions, and with C-terminus are x-, y-, z-ions, as shown in Figure 1.9. Although electron-transfer 
dissociation (ETD) becomes more and more common in identification of the multiply charged 
polypeptides,
96,97
 the fragmentation approaches used in this dissertation are traditional low-
energy collision-induced dissociation (CID) in ion-trap (IT) and quadrupole time-of-flight (Qq-
TOF) MS, and fragmentation of singly charged ions in matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) MS. The major fragment ions are series of b-
ions, y-ions, and internal ions formed between b and y.   
The process of low energy CID can be described by mobile proton theory. Protonation of 
peptide ions takes place in the acidic solution and/or during electrospray ionization. The protons 
prefer attaching to the basic sites such as N-terminal amine and the side chain of basic amino 
acid residues. They usually stay fixed at the strong basic sites such as lysine, arginine, and 
histidine, but those at the weak basic site (N-terminus of a peptide) move along the carbon 
backbone to form a heterogeneous population of peptide ions.
52
 Once the peptide parent ions 
were isolated for the dissociation in the collision cell, they are activated by increased resonance 
amplitude to collide with the buffer gas (e.g. helium). The kinetic energy is then converted into 
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internal energy in the peptide ions, which breaks the protonated amide bond, producing a series 
of fragment ions.
98,99
 Therefore, the presence and level of the fragment ions are predictable and 
reproducible, which provides a guideline for peptide sequencing with tandem MS.  
The principle of tandem MS in MALDI-TOF MS has also been studied.
52,100
 The peptides 
being fragmented in MALDI-TOF tandem MS are almost exclusively singly charged. Peptide 
fragmentation occurs after acceleration in the source. The fragment ions formed in the field-free 
drift region, travel side by side with their parent ions. Because fragment ions have smaller energy 
with smaller masses than parent ions, they are detected in the reflectron mode as described above. 
Ultraflex II MALDI-TOF/TOF MS (Bruker Daltonics, Bremen, Germany) used in this 
dissertation has a collision cell for CID function. To obtain a full MS/MS spectrum, the 
instrument also has a specific chamber (termed LIFT in Ultraflex II MALDI-TOF/TOF MS) to 
raise the kinetic energy of the parent ion and fragment ions to a level that the reflectror can focus 
all the ions to the detector. In MALDI-TOF tandem MS, a number of immonium ions, internal 
fragment ions, and neutral loss ions as well as less abundant b- and y-ions are usually 
observed.
52,100
 
Here, synthetic proline (Pro)-containing peptides with and without N-terminal acetylation 
were used to illustrate the peptide sequencing with tandem MS from either ESI-IT or MALDI-
TOF MS. Throughout the dissertation, peptide sequencing was performed by following the 
fragmentation rules demonstrated below. Further information on peptide identification will be 
presented in Chapter 5 and 6.     
Experimental. Acetyl-GQLPSFKIW (MH
+
theor.=1117.6041) and non-acetylated 
GQLPSFKIW (MH
+
theor.=1075.5935) were synthesized in the biotech center at University of 
Illinois at Urbana-Champaign, and dissolved into 0.1% FA aqueous solutions to make 1 mM 
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stock solutions. The stock solutions were further diluted with 0.1% FA aqueous solution to 1 M 
for Ultraflex II MALDI-TOF/TOF (Bruker Daltonics, Bremen, Germany) tandem MS analysis or 
with ACN/H2O (50/50, v/v) containing 0.1% FA to 100 M and 1 M for HCTultra ESI-IT 
(Bruker Daltonics, Bremen, Germany) tandem MS analysis.  
In MALDI-TOF tandem MS analysis, 1 L synthetic peptide and 1 L -CHCA (10 
mg/mL in ACN/H2O, 70/30, v/v) were mixed and spotted on a steel MALDI target. Singly 
charged masses of the acetylated and non-acetylated Pro-containing peptides were isolated for 
fragmentation. In ESI-IT tandem MS, samples were introduced into the system by direct infusion 
with a 250 L syringe at a flow rate of 4 L/min. 1-min segment run was acquired with active 
data-dependent tandem MS. FlexAnalysis and DataAnalysis softwares (Bruker Daltonics, 
Bremen, Germany) were employed to display the MS and MS/MS spectra from MALDI-TOF 
and ESI-IT tandem MS, respectively. BioTools and Sequence Editor (Bruker Daltonics, Bremen, 
Germany) were used to assist the investigation of tandem MS of the two synthetic peptides.  
Results and Discussions. The possibility of the cleavage sites in peptides subjected to 
collision-induced dissociation (CID) is highly related with its amino acid composition.
101
 In the 
examples of Pro-containing peptides with and without N-terminal acetylation, both ESI-IT 
(Figure 1.10) and MALDI-TOF (Figure 1.11) tandem MS produced a dominated y6 ion, 
although MALDI-TOF tandem MS also produced dominated internal fragment ions (e.g. PSFK 
and QLPSF) as expected.
52,100
  It has been reported that the most abundant cleavage occurs when 
Val, His, Asp, Ile, and Leu N-terminally bonds with Pro in ESI CID MS/MS.
102
 In our case, the 
y6 ion forms via cleavage between Leu and Pro, and the fixed charge at Lys may contribute to 
the observation of y6 ion in ESI-IT MS/MS (Figure 1.10). In addition, a study on fragmentation 
characteristics of CID in MALDI-TOF MS has shown Pro, Trp, Asp, and Arg have a strong 
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effect on amide bond cleavage,
100
 which is supported by b3 and b8 ions observed in MALDI-
TOF tandem MS (Figure 1.11). Besides Pro-containing peptides, acidic residues such as Asp and 
Glu in a peptide were apt to fragment at their C-terminus.
103
 These amino acid dependent 
signature fragment ions are especially useful for de novo sequencing. In addition, some manually 
introduced modifications on peptides which aid in producing signature fragment ions would help 
with peptide identification. For example, incorporation of N-terminal dimethylation was used for 
de novo sequencing of neuropeptides in tissue extract,
104
 and esterification of acidic residues or 
peptide C-terminus also improved fragmentation efficiency.
105,106
 
When comparing the MS/MS of N-terminal acetylated and non-acetylated peptides, the 
N-terminal acetylation, as the only difference between the structures of the two peptides, causes 
them to produce the same set of y-ions, and a set of singly charged b-ions with a mass difference 
of ~42 Da. This information can be used to assist the identification of the related but distinct 
peptides. An example of successfully applying this rule of related fragment ions to identify the 
glycine-extended peptides at low levels compared to their amidated counterparts is illustrated in 
Chapter 4. 
Interestingly, the fragment ion patterns also changed with different concentrations of 
peptides in our examples. For the peptides tested here, b-ions are the dominate ions when 
peptides are in high concentrations (100 M), while the complimentary y-ions become dominant 
when peptides are in low concentrations (1 M). Some studies have shown how the peptide 
fragment ion pattern changes with different solvents.
107
 It would be interesting to discover why 
and how the peptide fragment ion pattern changes with the peptide concentrations. The related 
studies will help us better understand the mechanism of CID for peptide fragmentation, and thus 
build up a better algorithm for peptide identification. It has been suggested that a tandem MS 
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spectrum library could be used for peptide identifications.
108,109
 The relationship between the 
fragment ion patterns and the solvents informed us to be careful with the negative false while 
using the tandem MS library. 
A single LC-MS run could produce hundreds of tandem MS as shown above. The 
development of data analysis software and database searching engines facilitates the peptide 
identification. The widely used database searching engines include Mascot
110
 and SEQUEST.
111
 
Since these programs were originally developed for protein identification, and thus are lack in 
the information on dedicated neuropeptide processing enzymes, more effort has been made 
towards neuropeptide prediction and neuropeptide precursor databases. For example, NeuroPred 
(http://neuroproteomics.scs.illinois.edu/neuropred.html) can be used to predict neuropeptides in a 
number of animal models.
112
 Swepep,
113
 EROP-Moscow oligopeptide database,
114
 and a 
bioactive peptide database
115
 provide information on the reported bioactive peptide sequences 
which tandem MS could be searched against. In addition, de novo sequencing is often required 
when database is not available, or unpredicated cleavages or PTMs occur. Several de novo 
sequencing programs such as PEAKS,
116
 PepNovo,
117
, and Lutefisk 
118
 have been used to assist 
manual de novo sequencing. The sequence tags are then searched against the protein or 
neuropeptide precursor databases or against translated nucleotide database in Basic Local 
Alignment Search Tool (BLAST) at http://blast.ncbi.nlm.nih.gov/Blast.cgi. More information on 
the peptide identification will be presented in Chapter 5 and 6. 
1.4.4 Peptide Quantitation 
Since neuropeptides are involved in most functions and behavior, neuropeptide level 
difference between two or more physiological states of biological systems is of more scientific 
interest in neuropeptidomics. MS is not inherently quantitative because of the complicated 
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relationship between physicochemical properties of peptides and mass spectrometric responses to 
peptides and their chemical environment. However, each individual peptide can be compared 
among different samples in several ways for relative quantitation. When a stable isotope labeled 
synthetic peptide is used as an internal standard, absolute quantitation can be realized.
37,119-121
 
For global peptide quantitation, MS-based approaches are generally used in relative quantitation 
with either labeling or label-free techniques. 
Labeling Quantitation. In protein quantitation, isotope labels can be introduced into 
proteins or peptides metabolically, chemically, enzymatically, or by spiking synthetic peptides as 
external standards.
122
 However, most endogenous peptide quantitation approaches are based on 
chemical labeling of the peptides extracted from nervous system tissue.
9,21,30-33
 
Stable isotope labeling quantitation is based on stable isotope dilution theory: A stable 
isotope labeled peptide is chemically identical to its native counterpart, and thus the two peptides 
behave identically during chromatographic and mass spectrometric analyses.
122
 Therefore, the 
control and experimental samples are labeled with light and heavy forms of labeling tags, and 
then combined for LC-MS or LC-MS/MS analysis. The mass difference introduced by labeling 
tags on the same peptide in different samples can be recognized by MS, and the quantitation on 
the peptide is achieved by comparing the relative peptide intensities or areas (Figure 1.2.A). In 
addition, tandem MS-based labeling quantitation (e.g. isotope tags for relative and absolute 
quantification or iTRAQ) has been applied for multiplex comparison.
123,124
 
Several aspects should be considered for developing or choosing isotopic labeling 
reagents.
9
 First, the reagent should have a universal reaction group to most peptides. Isotope-
coded affinity tag (ICAT), commonly used for protein quantitation, is limited to cysteine-
containing proteins or peptides. Therefore, it is not practical for neuropeptide quantitation 
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because few neuropeptides contain cysteine residues. In contrast, amino and carboxyl groups are 
common to all peptides except those with post-translational modifications blocking N- or C-
terminus. Therefore, acetic anhydride (d0 or d6), succinic anhydride (d0 or d4),
21
 
trimethylammoniumbutyrate (d0 or d9),
30,31
 and formaldehyde (d0 or d4)
125
 have been developed 
to target the peptide N-terminus and the -amino group of Lys, while methanol (d0 or d3) has 
been used to label the peptide C-terminus.
33
 Second, the reagent should be reactive enough for a 
reproducible and complete reaction, and stable enough for storage purpose. For example, acyl 
halides are good labeling reactants. However, they are too active to be controlled. Instead, 
anhydrides have a longer shelf life, and provide reproducible results.
9
 Third, the labeling 
products should be stable enough to afford the sequential LC-MS analysis. 
Trimethylammoniumbutyrate labels
126
 have been successfully applied in neuropeptide 
quantitation with ESI-Qq-TOF
32,75,127-131
 but not MALDI-TOF MS or LCQ ion trap MS due to its 
instability on the latter two mass spectrometers.
9
 Fourth, the label should provide large enough 
mass difference between the two peptides without affecting peptide detection.
9
 For isotope 
labeling based on deuterium or hydrogen, methanol and acetic anhydride provide 3-Da mass 
difference per label, and succinic anhydride (or formaldehyde) and trimethylammoniumbutyrate 
respectively cause 4-Da and 9-Da mass difference per amino group. Fifth, the heavy and light 
forms of the labeled peptides should co-elute on the LC column.
9
 Peptides labeled with single 
succinic anhydride have better co-elution than small peptides with multiply labels.
31
 Finally, the 
labeling reagent should be commercially available or easy to synthesize.
9
 Commercially 
available reagent succinic anhydride will be used in Chapter 3 for peptide quantitation. 
Label-free Quantitation. Although MS-based labeling quantitation plays an important 
role in peptide quantitation, it suffers from incomplete labeling, the increase in sample 
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complexity and sample preparation time, and high reagent costs. In contrast, label-free 
quantitation provides faster, cleaner, and more sensitive detection without introducing labeling 
tags. The typical label-free quantitation procedure is pretty similar to peptide identification. Each 
sample is separately prepared and analyzed by LC-MS or LC-MS/MS. Therefore, there is no 
limitation on the numbers of samples to compare. Label-free quantitation also provides higher 
dynamic range than stable isotope labeling, which is advantageous for global peptide 
quantitation.
122
 In addition, because of the simpler scheme and less sample preparation steps, 
label-free quantitation is good at quantifying the peptide in low levels (see Chapter 2 and 4). 
Peak intensity- or area-based comparative LC-MS and spectral counting-based LC-MS/MS are 
two approaches in label-free quantitation of proteins/peptides.
122,132,133
 The former one (Figure 
1.2.B) is based on the positive correlation between MS signals and ion concentrations,
134
 and is 
more prevalent in peptidomics.  
In peak intensity- or area-based comparative LC-MS, experimental steps from sample 
preparation to LC-MS analysis should be minimized and well controlled for high reproducibility 
from sample to sample. Normalization is generally required to account for the experimental 
variations. An ion with a specific m/z is detected in certain intensity at a particular time. 
Therefore, inaccurate m/z and retention time drift complicate the direct comparison among 
multiple LC-MS runs. Therefore, MS calibration and careful chromatographic peak alignment 
are essential for accurate quantitation. For a practical reason, a large set of data for comparison 
requires automated data analysis. Finally, statistical analysis such as Student t-test is performed 
to determine the significant changes among different samples.
135
  
Notes. During MS analysis for both quantitation approaches, very low or very high 
signals could be problematic for peptide quantitation. Very low signals are embedded among the 
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signal background, and it is hard to distinguish the contribution of peptides or background on the 
quantitation results. Very high signals could saturate the detector, which cause biased 
quantitation results.
122
 In addition, a systematic investigation on the application of numerous 
statistical analysis approaches is needed for MS-base quantitation. With the large volume of data 
and complexity of biological samples, appropriate statistical approaches are important to direct 
the experimental design and reach the meaningful result interpretations. 
1.5 Dissertation Overview 
The Sweedler group at University of Illinois at Urbana-Champaign developed, optimized, 
and employed multiple analytical tools to investigate molecules used in cell-to-cell 
communication in the nervous system. Since biological samples are usually heterogeneous, 
complicated, and sample-limited, these studies require high sensitivity, selectivity and a wide 
dynamic range of detection. Mass spectrometry (MS) provides fast, sensitive, accurate, and high-
throughput peptidomics analyses of neuropeptides in complex biological samples without 
requiring prior knowledge of the peptide sequences. Not only could MS provide the peptide 
sequence information, MS is also suitable to quantify peptides to correlate peptide level changes 
to specific traits, conditions and even behavior.
20-22
 In such cases, we are able to answer 
questions in both “what” and “how”, which uncovers the molecular hallmarks in the cell-to-cell 
communication. The work presented in this dissertation falls into the theme of identifying and 
quantifying neuropeptides with MS-based approaches. The samples range from mouse pituitary 
and Drosophila heads, which are well characterized nervous system models, to glial cell cultures, 
which are of active exploration recently.  
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The dissertation introduces neuropeptidomics and mass spectrometric techniques, and 
briefly overviews MS-based peptide identification and quantitation approaches in recent 
neuropeptidomics. The peptide identification rules demonstrated in Chapter 1 have been applied 
throughout the dissertation, especially in Chapter 5 and 6. Chapter 5 shows that the peptide 
profiles of different types of glia and their peptide releasates regulated by chemical stimuli were 
detected, and some of these peptides were identified. Neurons and glia are the two main types of 
cells in the central nervous system. The studies on neurons have been much more advanced than 
that on glia. Fortunately, more and more studies have been focused on glia in terms of their 
locations, types, cellular and sub-cellular structures, and signalling molecules.
136-142
 Our work 
provides a peptide database for future glia studies. In Chapter 6, optimized instrument conditions 
were investigated to produce high quality tandem MS from small peptides (5mer). High mass 
accuracy and mass resolving power are the keys for small peptide identification. The collected 
tandem MS in this work would be used to build a computational model for small peptide 
identification in the complicated biological samples. 
Different MS-based quantitative approaches were discussed with specific applications in 
Chapters 2-4. In Chapter 2, a label-free quantitation approach was developed based on isolated 
parent ions in tandem MS mode of MALDI-TOF MS. This approach allowed quantification of 
an ectopic peptide MII in Drosophila heads to disclose the mechanism of a transcription factor 
named DIMM. In this study, DIMM was shown to confer upon non-peptidergic cells a complete 
and efficient peptide processing pathway. In Chapter 3, a well-studied MS-based labeling 
quantitation approach was utilized to invesitage the peptide amidation in mouse pituitary. In this 
work, we searched for peptides whose production was sensitive to the deficit of peptide 
amidation enzyme and/or different copper amount in diet, trying to correlate the peptide level 
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changes with the abnormal behavior of mouse under these different manipulations. Additionally, 
the presence and level changes of immature forms of the amidated peptides under these 
manipulations have also been studied (see Chapter 4). 
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1.6 Figures 
 
 
 
 
Figure 1.1. Work flow of sample preparation, MS-based detection, and data analysis for peptide 
identification. The schematic outlines peptide extraction from the cells or tissue samples, peptide 
desalting and pre-concentration, peptide analysis with either direct MS or LC-MS. Both matrix-
assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI) MS could be 
used to obtain the mass spectrum and tandem mass spectrum. Peptide sequencing was conducted 
by matching the fragment ions with the amino acid residues. 
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Figure 1.2. Work flow of MS-based peptide quantitative studies. (A). Stable isotope labeling. 
The control and experimental samples are labeled with light and heavy forms of labeling 
reagents before they are combined for further sample preparation and LC-MS analysis. The 
relative amount of each peptide is calculated based on the intensity or area ratio of the isotope-
labeled peptide pairs. (B). Label-free quantitation. The control (CTL) and experimental (EXP) 
samples are subjected to individual but identical sample preparation and LC-MS analysis. The 
spectra are aligned for comparison. The quantification is based on the comparison of peak 
intensity or area of the same peptide in the parallel runs. 
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Figure 1.3. The structures of commonly used matrix for matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).  
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(A) 
 
(B) 
 
 
Figure 1.4. Schematic of MALDI-TOF MS. (A) Ionization of analytes by MALDI: a laser beam 
hits the co-crystals of analytes and matrix, carries the protonated analyte ions into the gas phase. 
(B) Mechanism of TOF analyzer interfaced with MALDI: the protonated analyte ions are 
accelerated by an electric field, and fly through the field-free drift region toward the detector. 
The ions can be detected with either linear mode or reflectron mode. Figure (A) is reprinted from 
“K. Boonen, B. Landuyt, G. Baggerman, S.J. Husson, J. Huybrechts, L. Schoofs: Peptidomics: 
The integrated approach of MS, hyphenated techniques and bioinformatics for neuropeptide 
analysis. J. Sep. Sci. 2008, 31, 427-445”. Copyright © Wiley-VCH Verlag GmbH & Co. KGaA. 
Reproduced with permission. Figure (B) is adapted from Bruker Ultraflex II MALDI-TOF/TOF 
MS manual with permission. Copyright © Bruker Daltonics. 
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Figure 1.5. (A). Direct MALDI-TOF MS and (B). LC-MALDI-TOF MS analysis of glial cell 
extracts. LC separation prior to MALDI-TOF MS analysis help resolve more peaks to be 
detected by reducing the ion suppression. 
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Figure 1.6. Schematic of ESI process. The acidic analyte solution is sprayed through a needle 
maintained at a high voltage to form a Taylor cone, and the droplets of analytes emitted from the 
Taylor cone went through the cycle of solvent evaporation and Coulombic explosion to form the 
gasneous protonated ions. The figure is reprinted from “K. Boonen, B. Landuyt, G. Baggerman, 
S.J. Husson, J. Huybrechts, L. Schoofs: Peptidomics: The integrated approach of MS, 
hyphenated techniques and bioinformatics for neuropeptide analysis. J. Sep. Sci. 2008, 31, 427-
445”. Copyright © Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
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Figure 1.7. Schematic of ESI-Qq-TOF.
45
 Protonated ions created via ESI are guided through the 
Qq-TOF analyser by the voltage and vacuum gradient. The first quadrupole focuses the ions, the 
second quadrupole allows all ions to pass (MS scan) or filters a certain ions for MS/MS taking 
place in the collision cell. The ions in either MS or MS/MS scans are analyzed by an orthogonal 
TOF analyzer. The figure is reprinted from “K. Boonen, B. Landuyt, G. Baggerman, S.J. Husson, 
J. Huybrechts, L. Schoofs: Peptidomics: The integrated approach of MS, hyphenated techniques 
and bioinformatics for neuropeptide analysis. J. Sep. Sci. 2008, 31, 427-445”. Copyright © 
Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
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Figure 1.8. Schematic of ESI-IT MS (HCTultra). The protonated ions produced via ESI are led 
into the glass capillary, focused by a skimmer, a dual octopole, and multiple lens, and then 
trapped into the center of the ion trap. By adjusting the radiofrequency (RF), the ions with 
increasing m/z are ejected and detected at the detector. The figure is adapted from Bruker 
HCTultra ESI-IT MS manual with permission. Copyright © Bruker Daltonics. 
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Figure 1.9. The structure of a peptide and nomenclature system of the fragment ions: a-, b-, c-
ions contain the N-terminus, and x-, y-, z-ions contain the C-terminus of a peptide. The 
dominated ions produced in the widely used collision-induced dissociation are b- and y- ions. Rn 
(n = 1–4) are the side chains of different amino acid residues. 
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Figure 1.10. Electrospray ionization ion trap tandem mass spectra (ESI-IT MS/MS) of synthetic 
proline-containing peptides in (A) 100 M and (B) 1M. The two top spectra are from acetyl-
GQLPSFKIW (m/z = 559.3, z = 2), and the two bottom ones are from GQLPSFKIW (m/z = 
538.3, z = 2). The assignment of b- and y-ions matches expected fragments within 0.2 Da. 
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Figure 1.11. Matrix-assisted laser desorption/ionization time-of-flight tandem mass spectra 
(MALDI-TOF MS/MS) of synthetic (A) acetyl-GQLPSFKIW (MH
+ 
= 1117.60) and (B) 
GQLPSFKIW (MH
+ 
= 1075.59). The assignment of b-, y-, and internal fragment ions matches 
expected fragments within 0.2 Da. 
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Chapter 2. LC-MS Investigation of DIMM as a Master Regulator in 
Drosophila Peptidergic Cells 
Adapted from (1) Y. Hamanaka, D. Park, P. Yin, S.P. Annangudi, T.N. Edwards, J.V. Sweedler, 
I.A. Meinertzhagen, P.H. Taghert, Transcriptional orchestration of the regulated secretory 
pathway in neurons by the bHLH protein DIMM. Curr. Biol. 20, 2010, 1–10. Reproduced with 
permission. Copyright © 2010, Elsevier. (2) D. Park, P. Yin, J.V. Sweedler, P.H. Taghert, The 
Drosophila bHLH protein DIMM directly targets CG13248, a gene encoding a putative cationic 
amino acid transporter. In preparation. Copyright © publisher to be announced.  
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2.2 Introduction 
In peptidergic cells, neuropeptide precursors are synthesized in the endoplasmic 
reticulum and traverse the Golgi apparatus. The processed neuropeptides are packaged into, and 
then released from large dense-core vesicles (LDCVs) in a regulated secretory pathway.
2,3
 
LDCVs containing neuropeptides are distinguished in appearance and size (>60 nm in diameter) 
from small clear-core vesicles (SCCVs — 30–50 nm) which contain neurotransmitters such as 
acetylcholine and GABA.
4
 Both LDCVs and SCCVs are located in specific neurons and release 
their molecular contents via Ca
2+
-triggered exocytosis.
5
 In the regulated secretory pathway, 
neuropeptide precursors are enzymatically cleaved and post-translationally modified to produce 
the bioactive neuropeptides. The regulated secretory pathway and the proteins that control it have 
been of intense scientific interest.
6-11
 However, few studies have addressed the underlying 
genetic mechanisms that direct the maturation of peptidergic cellular properties and provide 
proper scaling and modulation of the regulated secretory pathway. 
Peptidergic neurons are known to have an enhanced ability to accumulate and/or release 
neuropeptides compared to those that primarily release classical neurotransmitters. For example, 
perinatal pancreatic acinar cells produced secretory proteins but secreted them constitutively.
12
 
PC-12 and AtT-20 cell variants were deficient when forced to display the regulated secretory 
pathway.
13,14
 Recent genetic studies in Drosophila showed intrinsic differences in the capacity of 
neurons to accumulate neuropeptides ectopically.
15,16
 Here we examined the hypothesis that, in 
Drosophila, a specific basic helix-loop-helix (bHLH) transcription factor gene dimmed (dimm) is 
fundamental to that intrinsic mechanism, and the protein DIMM underlies the multi-level 
organization of a major cellular phenotype — the peptidergic neurosecretory cell. 
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In Drosophila, DIMM expression is restricted to neurosecretory cells which produce 
various neuropeptides.
17,18
 In loss-of-function mutants, dimm-expressing cells survive but fail to 
accumulate neuropeptides or dedicated processing enzymes.
17,19,20
 With a gain-of-function 
strategy, Hamanaka and Park confirmed the inability of non-peptidergic neurons in Drosophila 
to accumulate appreciable amounts of ectopic neuropeptides, and showed that failure was 
overcome by supplying ectopic DIMM.
1
 In this work, we investigated whether DIMM-
dependent ectopic neuropeptide accumulation is accompanied by normal posttranslational 
processing. Because mass spectrometry (MS) has been successfully applied to characterize the 
actual forms of neuropeptides in insects including Drosophila,
21-24
 we employed MS-based 
methods to study DIMM-dependent peptide processing. The MS results combined with 
collaborators’ molecular biological results demonstrated that DIMM conferred upon non-
peptidergic photoreceptor neurons a complete and efficient peptide processing pathway and 
several other critical cellular properties that are characteristic of dedicated peptidergic neurons.  
Together, our observations support the hypothesis that DIMM organizes the specialized features 
of the peptidergic neurosecretory cell fate.   
DIMM is a transcription factor, and to date its only defined gene target is 
peptidylglycine-α-hydroxylating monooxygenase (PHM) which encodes a neuropeptide 
amidating enzyme.
19,25
 Here we further examined DIMM’s role in regulating gene expression. 
With microarray profiles in a genome-wide analysis of DIMM activity, quantitative real time 
PCR, and conventional PCR, 13 gene candidates including PHM were selected for further 
studies. Multiple independent experiments including RNA in situ hybridization at embryo, 
chromatin immunoprecipitation using adult heads, and the functional luciferase reporter assay on 
in vitro cell culture, as well as an MS-based approach, were used to further examine the 13 
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candidate genes for DIMM target. An MS-based label-free approach was developed to quantify 
the ectopic peptide MII in the adult Drosophila heads with or without the knock-down of the 
target candidates using RNA interference (RNAi). We applied an internal standard, an 
endogenous peptide not affected by our genetic manipulations for normalization in the relative 
quantitation of MII. In this way, we quantified ectopic peptide MII using LC-MALDI-TOF MS. 
Together with other assays, we concluded that CG13248 is a DIMM target gene, which involves 
peptide processing.  
2.3 Experimental 
2.3.1 MS-based Approaches for Ectopic Peptide Identification 
Sample Preparation. The ectopic MII peptide precursor (UAS-ppMII) was constructed 
in the Paul Taghert group.
1
 The single and double transgenic fly lines (GMR > ppMII and GMR 
> ppMII; dimm) were generated and raised as described.
1
 Fly heads were dissected, frozen, and 
then sent to us for MS analysis. The frozen fly heads of the two transgenic lines (GMR > ppMII 
and GMR > ppMII; dimm) were respectively homogenized in acidified acetone (40:6:1, 
acetone:water:concentrated HCl, v/v/v). The homogenate was centrifuged at 11,000 rpm for 5 
min, and the supernatant was transferred to a vial placed in a SpeedVac (Thermo Electron Co.). 
Acetone in the extract solution was then evaporated, and an aqueous sample solution was 
obtained for subsequent MS analysis.  
Direct MALDI-TOF MS analysis. The aqueous sample solutions (1 L) of fly head 
extracts from the single and the double transgenic lines (GMR>UAS-ppMII and GMR>UAS-
ppMII; UAS-dimm) were spotted on a stainless steel MALDI target, and co-crystallized with 1 
L of 50 mg/mL 2,5-dihydroxybenzoic acid (Sigma) in a acetonitrile/water (70/30, v/v) solution. 
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Ultraflex II MALDI-TOF/TOF MS (Bruker Daltonics, Bremen, Germany) was used to detect the 
peptides in the mass range of 800-6000 Da.  
LC-MALDI-TOF MS. The aqueous sample solutions (5 L) of fly head extracts from 
the single and the double transgenic lines (GMR>UAS-ppMII and GMR>UAS-ppMII; UAS-
dimm) were respectively separated with a reverse phase column (Alltech Associates Inc., Alltima 
HP C18, 150 mm × 300 m, 3 m particle diameter, 100 Å pore size) at a flow rate of 2 L/min 
in a capillary LC instrument (Waters). The peptides were eluted with a gradient of 2-80% 
acetonitrile in the aqueous solution with 0.1% (v/v) formic acid (FA) and 0.01% (v/v) 
trifluoroacetic acid (TFA). The LC system is coupled to a robotic fraction collector 
PROTEINEER fc (Bruker Daltonics, Bremen, Germany). A total of 24 one-minute fractions 
were collected and spotted on a MALDI target for each sample. 1 L of -cyano-4-
hydroxycinnamic acid (Sigma) in acetonitrile/water (70/30, v/v) solution was used as matrix for 
MALDI-TOF MS analysis performed by Ultraflex II as described above. Four batches of 
samples were analyzed to get representative results. The potential presence of the peptide was 
determined by mass matching between the theoretical mass and the peak at signal-to-noise ratio 
of 3 within 50 ppm. 
Peptide Reduction/Alkylation and MS Analysis. The pH of fly head extract from the 
double transgenic line (GMR>UAS-ppMII; UAS-dimm) was adjusted to basic with 1 M 
NH4HCO3 before the reaction. The reduction was performed by adding 8 L of 200 mM 1,4-
dithio-DL-threitol (DTT) in 100 mM NH4HCO3 into 30 L of extract, followed by 10 min of 
boiling in the water bath. The reaction system was then incubated in the room temperature for 
about one hour before 6.4 L of 1 M iodoacetamide (IAM) in 100 mM NH4HCO3 was added 
into the system for alkylation. After one hour, 32 L of DTT solution was added to remove the 
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unreacted IDA. After the reaction was complete, a small portion of the sample was pre-cleaned 
with a C18 ZipTip (Millipore) before being spotted onto a MALDI target. 50 mg/mL DHB was 
used as matrix for MALDI-TOF MS analysis. The rest of the sample was desalted with a 
PepClean C18 spin column (Pierce), and the eluent was dried to about 10 L in a SpeedVac 
(Thermo Electron Co.). The 10 L aqueous sample was separated with the same LC system 
described above, and subjected to online ESI tandem MS analysis with HCTultra ESI ion-trap 
MS (Bruker Daltonics, Bremen, Germany). A preferred m/z for fragmentation was set to 972.0±
0.5, a double charged MII peptide ion. MS/MS spectra were analyzed using the DataAnalysis 
and BioTools software package (Bruker Daltonics, Bremen, Germany). The peptide identity was 
confirmed with fragment ion mass matches within 0.1 Da. 
2.3.2 MS-based Relative Quantitation of Ectopic Peptide  
Validation of the Label-free Quantitation Approach. Peptide mix (Bruker Daltonics, 
Bremen, Germany) for testing the label-free quantitation approach included bradykinin (1-7), 
angiotensin II, angiotensin I, substance P, bombesin, renin substrate, ACTH clip (1-17), ACTH 
clip (18-39), somatostatin 28, whose masses range from 700 Da to 3000 Da. The mix was made 
in different concentrations (0.02, 0.05, 0.125, 0.2, 0.333, 0.5, 1, and 2 M) in 0.1% FA and 
0.01% TFA aqueous solutions to test the relationship between peptide peak intensities/areas and 
concentrations. Specifically, bradykinin (1-7) and angiotensin II were chosen as targeted 
peptides. In order to further study the effect of chemical environment in this label-free approach, 
1 M bradykinin (MH+ at 1060.5687) was mixed with different concentrations of peptide mix 
(0.02, 0.1, 0.5, 1, and 2 M), and then both bradykinin and angiotensin II was examined for the 
intensities/areas vs. concentrations relationship. The peak intensities were obtained by summing 
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the intensities of isolated particular parent ions using Ultraflex II MALDI-TOF/TOF MS (Bruker 
Daltonics, Bremen, Germany) in tandem MS mode. The instrument parameters such as laser 
power were kept constant. Three spots per sample were analyzed as technical replicates. 
Sample Preparation. The fly heads of the control (GMR>UAS-ppMII; UAS-dimm) and 
the experimental transgenic lines (GMR>UAS-ppMII; UAS-dimm; RNAi on one gene) were 
respectively homogenized in acidified acetone (40:6:1, acetone:water:concentrated HCl, v/v/v; 
10 L/head). The homogenate was centrifuged at 11,000 rpm for 5 min, and the supernatant was 
transferred to a vial placed in a SpeedVac (Thermo Electron Co.). Once dried, the extracts were 
reconstituted with 2% acetonitrile aqueous solution with 0.1% FA and 0.01% TFA for 
subsequent quantitative analysis.  
Labeling Quantitation. In the labeling quantitation, the labeling reaction with succinic 
anhydride was conducted as previously described.
26
 Briefly, 2 L of 2 M light and heavy forms 
of succinic anhydride (Sigma Aldrich) in dimethyl sulfoxide (DMSO) were used to label the 
control and experimental samples each time after the sample solutions were adjusted to be basic. 
After the reaction, the labeled control and experimental samples were combined before being 
desalted using C18 spin columns (Pierce, Rockford, IL). The combined and desalted samples 
were then analyzed with LC-MALDI-TOF MS as described above. 5 L samples were separated 
with a reverse phase column (Alltech Associates Inc., Alltima HP C18, 150 mm × 300 m, 3 m 
particle diameter, 100 Å pore size) at a flow rate of 2 L/min. Solvent A contains 95% water, 
5% acetonitrile, 0.1% FA, and 0.01% TFA, and Solvent B contains 5% water, 95% acetonitrile, 
0.1% FA, and 0.01% TFA. The 45-min gradient started from 2% B to 20% B in 10 min, to 40% 
B in another 15 min, continued to 80% B in 7 min, and stay at 80% B for 3 min before ramping 
back to 2% B. The fraction collection started at 20 min, and a total of 24 one-minute fractions 
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were collected on a MALDI target for each sample. 1 L of -cyano-4-hydroxycinnamic acid 
(Sigma Aldrich) in acetonitrile/water (70/30, v/v) solution was used as matrix for MALDI-TOF 
MS analysis in the mass range of 600-5000 Da. The relative peak intensities in the peak pair 
were used to indicate the relative amount of peptides between control and experimental samples. 
Label-free Quantitation of MII. In the label-free quantitation approach, Drosophila 
head extracts were analyzed with LC-MALDI-TOF MS described above. Endogenous 
Drosophila peptide Drm-PK-2 (MH
+
 at 942.59) and ectopic peptide MII (MH
+ 
at 1710.69) have 
been well studied in Drosophila previously,
1,23,27
 and their presence was determined by mass 
matching between the theoretical masses and the experimental masses at signal-to-noise ratio 
above 3 within 20 ppm. Drm-PK-2 and MII were respectively isolated with MALDI-TOF 
tandem MS, and the summed intensities of the isolated parent ions were used to reflect the 
amount of the peptides. The intensity of MII in the experimental sample was compared to that in 
the control within the same sample set, and normalized with Drm-PK-2 in the corresponding 
samples. Based on the null hypothesis there is no difference between control and experimental 
samples, we used Student’s t-test for statistical analysis with at least three biological replicates. 
2.4 Results and Discussions 
2.4.1 DIMM Confers the Biochemical Properties of a Peptidergic Cell  
The immonoassays showed that when photoreceptors, a class of non-peptidergic cells, 
mis-expressed either pigment dispersing factor (Pdf) or dimm alone, immunoreactivity to PDF 
was lacking in these non-peptidergic cells. In contrast, with double mis-expression (GMR > 
dimm, Pdf), photoreceptors displayed ectopic PDF immunoreactivity. These results indicated the 
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accumulation of ectopic neuropeptide by photoreceptor neurons was completely dependent on 
dimm co-misexpression.
1
  
We next asked whether DIMM-dependent ectopic neuropeptide accumulation is 
accompanied by normal post-translational processing. We utilized mass spectrometric methods 
to investigate DIMM-dependent peptide processing. We constructed a novel neuropeptide 
precursor (called ppMII) consisting of the 16 amino acid MII secretory peptide from the 
poisonous snail Conus
28
 fused to the Drosophila neuropeptide PDF precursor at a position that 
substitutes for the PDF peptide (Figure 2.1). If this precursor was fully processed, we predicted 
detection of MII peptide at m/z 1710.69, assuming C-terminal amidation and two separate 
disulfide bonds. The peptide content of head extracts from the single and double transgenic lines 
(GMR > ppMII and GMR > ppMII; dimm) was analyzed using matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF MS). The mass of the predicted MII 
peptide was observed in the double transgenic line but not in the single transgenic line (Figure 
2.2). To confirm the assignment of this peak, we reduced the disulfide-bonds with DTT and then 
alkylated the thiols with iodoacetamide. The mass spectrum of the extracts after the reaction 
showed a peak consistent with the theoretical mass shift from the MII peptide (m/z 1942.93) 
(Figure 2.3). After reduction/alkylation, the identity of this fully processed MII peptide was 
confirmed using electrospray ionization ion-trap tandem mass spectrometry (ESI-IT-MS/MS) 
(Figure 2.4). Additionally, no evidence, in either single or double transgenic lines, for any of 31 
possible ppMII processing intermediates was found with liquid chromatography (LC) coupled to 
MS, a technique well suited to resolving individual peptides in complex biological samples. 
Together, these data strongly support the hypothesis that non-peptidergic cells can not normally 
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process neuropeptide precursors. However, ectopic DIMM confers upon such cells a complete 
and efficient post-translational processing pathway for precursors of amidated secretory peptides. 
In addition, our collaborators’ electron microscopy (EM) results showed that DIMM mis-
expression alters the vesicle phenotype in Drosophila photoreceptor terminals. Vesicles that 
resembled the peptidergic LDCVs were observed in the photoreceptors of GMR>dimm and 
GMR>dimm, Pdf, but not GMR>Pdf. Immunogold EM also demonstrated that the accumulated 
ectopic PDF was actually localized in the ectopic LDCVs. At the same time, DIMM-expressing 
photoreceptors lost several intrinsic features. For example, their terminal lacked normal 
presynaptic release sites; they didn’t have detectable histamine and lacked light-absorbing 
rhabdomeres.
1
 
In summary, DIMM-driven cellular properties within transformed photoreceptor cells 
greatly resembled those of normal peptidergic neurosecretory cells. The potent and coordinated 
effects of DIMM in non-peptidergic neurons indicate that DIMM normally promotes a complete 
program of neurosecretory cell differentiation. This conclusion in turn highlights a need to define 
mechanisms of DIMM’s normal action. 
2.4.2 Quantitation of Ectopic Peptide to Evaluate Peptide Processing Machinery 
In order to evaluate DIMM-regulated peptide processing, the level change of the ectopic 
peptide MII was examined between the double transgenic lines (GMR>UAS-ppMII; UAS-dimm) 
and the ones with one gene candidate knocked down by RNAi. Two quantitative mass 
spectrometry approaches have been used to semi-quantify MII in Drosophila head extracts. The 
first involves labeling and is well validated.
26,29
 The labeling approach involves multiple sample 
handling steps and is less effective for low concentration samples in small volume. In addition, 
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the presence of multiple experimental samples with RNAi on various gene candidates versus one 
control sample determined that a label-free approach is more efficient than labeling approach. 
Therefore, we also developed a label-free approach based on MALDI-TOF MS analysis here.  
Standard peptides from 700 Da to 3000 Da were used to validate the label-free approach. 
As two examples of peptides in the peptide mix, the intensities/areas of bradykinin (1-7) and 
angiotensin II increased with their concentrations (Figure 2.5.A and B). When different 
concentrations of bradykinin were added into the same concentration of the peptide mix, the 
intensities/areas of bradykinin positively reflected its changing concentrations (Figure 2.5.D), 
while the intensities/areas of angiotensin II as one member in the peptide mix almost kept 
constant (Figure 2.5.C). Therefore, the intensities/areas of the parent ion peak isolated in the 
MALDI-TOF tandem MS mode positively correlates the amount of the peptide when the 
instrument parameters are consistent, the chemical environment of the peptide of interest is 
similar, and the total ion acquisition is equivalent for each measurement.   
MII was not observed after labeling because the low levels of MII present in Drosophila 
head extracts and sample losses during multiple sample handling steps prevented its detection. In 
contrast, the label-free approach using MALDI-TOF tandem MS was successfully applied to 
detect and quantify MII when one DIMM-regulated gene candidate was manipulated. As shown 
in Figure 2.6, MII in the experimental sample (CG3832, or PHM) was significantly decreased 
from that in the control sample (2A3). To reduce experimental errors, we selected the 
endogenous peptide Drm-PK-2 as an internal standard to normalize MII intensity before 
comparison.  In both labeling and label-free quantitation, Drm-PK-2 showed equal intensities in 
the control (2A3) and experimental (CG3832) samples (Figure 2.7), which supports the use of 
Drm-PK-2 as an internal standard as it is not affected by genetic manipulations. After 
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normalization to Drm-PK-2, relative MII levels were semi-quantified. We then determined if MII 
production was affected by the interference of ten DIMM-regulated genes and one DIMM-
unrelated genes ETH as negative control.  
As expected, the negative control (ETH-RNAi) did not alter MII levels compared to 
controls, while the interference of CG3832 (PHM), a DIMM activated gene, induced significant 
decrease in MII levels (p<0.01). CG 1275 RNAi, encoding a cytochrome b561 most related to 
the b561 protein intrinsic to chromaffin cell granule membranes, also significantly reduced MII 
levels (p<0.05). Cytochrome b561 protein is known to support the enzymatic functions of 
dopamine -monooxygenase and PHM by driving ascorbate regeneration within vesicles in 
cooperative manners.
30
  Interestingly, our results also showed the decrease in CG13248, which 
encodes the cationic amino acid transporter and homologous to mammalian CAT4 protein, 
significantly reduced MII in Drosophila head (p<0.05). CG13248 is enriched in the brain,
31
 and 
important for the nitric oxide signalling.
32
 Besides, the interference of CG17293 tends to 
decrease MII levels (p<0.1). CG17293 contains the WD repeat domain, similar to WDR82 
protein which participates in the histone H3-Lys4 trimetylation for the transcription initiation,
33
 
and the RNA interference of CG17293 caused extremely contracted chromosome and short 
spindles in the mitosis.
34
 CG17293 also likely encodes components of the cytoskeleton, and 
hence involves the vesicle trafficking or localization. There was no obvious difference in MII 
level when other candidate genes were interfered. 
Besides MS study of Drosophila adult heads, RNA in situ hybridization at embryos, 
chromatin immunoprecipitation using adult heads, and the functional luciferase reporter assay on 
in vitro cell culture were also performed by our collaborators to better select the DIMM-
regulated gene for peptide processing. Throughout four independent validation experiments, we 
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found that at least three genes, CG3832, CG1275, and CG13248, are possible direct DIMM 
targets. Since CG13248 is homologous to mammalian CAT4, we referred it as dCAT4. Further 
tests showed that most dCAT4 expressing cells were DIMM positive; knocking down dCAT4 
did not affect DIMM expression, while a dimm knock-down reduced both DIMM and dCAT4; 
and the mis-expression of DIMM in non-peptidergic cells caused the ectopic dCAT4 expression. 
In summary, our results suggest that dCAT4 gene is a 2nd gene besides PHM directly 
regulated by DIMM for amidated peptide maturation.  
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2.5 Figures 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. ppMII fusion protein compared with the original preproPDF. The predicted fully 
processed MII peptide consists of 16 amino acids with C-terminal amidation and two disulfide 
bonds. The figure is reprinted from Reference (17) with permission. 
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Figure 2.2. MALDI-TOF mass spectra of the brain extracts from the single transgenic line 
GMR>UAS-ppMII (top) and the double transgenic line GMR>UAS-ppMII; UAS-dimm (bottom). 
The peak at m/z 1710.62 (z=1) matches the expected MII peptide within 40 ppm. The figure is 
reprinted from Reference (17) with permission. 
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Figure 2.3. MALDI-TOF mass spectra of the brain extracts from the double transgenic line 
GMR>UAS-ppMII; UAS-dimm before (top) and after (bottom) reduction/alkylation. The insert 
includes zoom-in mass spectra of the MII peptide peak before reduction/alkylation at m/z 
1710.62 (upper insert, z=1) and after the reaction at m/z 1943.03 (bottom insert, z=1). The figure 
is reprinted from Reference (17) with permission. 
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Figure 2.4. ESI-IT tandem mass spectrum of MII peptide after reduction/alkylation (m/z=972.0, 
z=2). The assignment of b- and y-ions matches expected fragments within 0.07 Da. 
R=CH2CONH2. The figure is reprinted from Reference (17) with permission. 
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Figure 2.5. The correlation between peak intensities/areas of the isolated parent ion in MALDI-
TOF tandem MS mode and peptide concentrations. (A). Peak intensities/areas of bradykinin (1-
7) (MH
+
=757.40) in the standard peptide mix increases with increasing bradykinin (1-7) 
concentrations. (B). Peak intensities/areas of angiotensin II (MH
+
=1046.54) in the standard 
peptide mix increases with increasing angiotensin II concentrations. (C). Peak intensities/areas of 
angiotensin II in the standard peptide mix (S) stay even when the same concentrations of 
standard peptide mix is mixed with different concentrations of bradykinin (BK, MH
+
=1060.57). 
(D). Peak intensities/areas of bradykinin (BK, MH
+
=1060.57) increases with increasing BK 
concentrations mixed with the same concentration of the standard peptide mix (S). 
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Figure 2.6. Isolated parent ion in MALDI-TOF tandem MS mode for relative quantitation of MII 
(MH
+
=1710.69) in the control (2A3) and experimental (CG3832) samples. The intensity ratio of 
MII in CG3832 to that in 2A3 is 0.54. 
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Figure 2.7. Labeling and label-free results from endogenous peptide Drm-PK-2 (MH
+
=942.59). 
(A). MALDI-TOF mass spectrum of labeled Drm-PK-2 with light form of succinic anhydride in 
the control (2A3) and with heavy form of succinic anhydride in the experimental (CG3832). The 
relative intensity ratio of MII in CG3832 to that in 2A3 is 0.95. (B). Isolated parent ion in 
MALDI-TOF tandem MS mode for relative quantitation of Drm-PK-2 in the control (2A3) and 
experimental (CG3832) samples. The intensity ratio of Drm-PK-2 in CG3832 to that in 2A3 is 
1.02. 
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Figure 2.8. MII levels in the experimental samples with RNAi of a certain DIMM-regulated gene 
compared to that in the control samples. Error bar, SEM. Student’s t-test: ***, p<0.01; **, 
p<0.05; *, p<0.1. 
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Chapter 3. MS-based Quantitative Analysis of Genetic and Dietary 
Effects on Peptides in Mouse Pituitaries 
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3.1 Notes and Acknowledgments 
Following the investigation of DIMM-dependent genetic mechanism of neuropeptidergic 
cell maturation, we examined how post-translational processing with the dedicated enzymes 
affects the neuropeptide production in this and the next chapters. This is collaborative work 
between Betty A. Eipper’s group at University of Connecticut and Jonathan V. Sweedler’s group 
at University of Illinois at Urbana-Champaign. The animals were prepared and dissected in the 
Eipper group, and the MS-related analysis was conducted in the Sweedler group. Bruce R. 
Southey performed the statistical analysis on the raw data of peak intensity ratios, which is an 
indispensable part of this project. I’d like to acknowledge Suresh P. Annangudi for the initial 
contribution on this project, and Xiaowen Hou for sharing experiences and information on MS-
based labeling quantitation. This work is supported by National Science Foundation (NSF) 
through CHE-0526692, and National Institutes of Health (NIH) through DA018310 and 
DK32949. 
3.2 Introduction 
Neuropeptides are involved in many functions and behavior such as feeding, sleeping, 
pain, and learning. A large number of studies have been performed to investigate the peptide 
level changes in the samples upon different treatments or in different physiological states. 
Radioimmunoassays (RIAs) are traditional approaches to measure the subtle changes in peptide 
levels for this purpose.
1,2
 However, most antisera lack in specificity by cross-reacting with N- 
and C-terminally extended peptides, and they may not be able to differentiate peptides with or 
without post-translational modifications. In addition, RIAs require prior knowledge of the target 
peptides, and time/expense to develop and characterize them. The advent of mass spectrometry 
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(MS) has broken through these limitations by providing the accurate peptide mass and sequence 
information without prior knowledge of peptides. With stable isotopic labeling, MS has been 
successfully applied to correlate peptide level changes to specific traits, conditions and even 
behavior.
3-5
 
Neuropeptides are generally derived from their large precursors which are usually 
cleaved at the basic sites by processing enzymes such as prohormone convertase 1 (PC1, also 
known as PC3), prohormone convertase 2 (PC2), and prohormone/proprotein convertase 5A.
6
 
The cleavage products then have the basic sites removed by carboxypeptidase E (CPE), and are 
post-translationally modified before being released through a regulated secretory pathway. A 
number of enzymes are involved in the post-translational modifications, among which 
peptidylglycine -amidating monooxygenase (PAM) is responsible for peptide amidation.7-10 
Peptide amidation converts the C-terminal glycine residue of a peptide to an amide group which 
can be essential for the peptide to bind to its receptor.  
Elimination of the PAM gene prevents formation of amidated peptides and is lethal in 
both Drosophila
11
 and mouse.
12
 PAM heterozygous (PAM
+/-
) mice, with lower PAM activity 
than wildtype (WT) mice, survive to adulthood and reproduce,
13
 but exhibit a variety of deficits. 
For example, PAM
+/-
 mice are unable to maintain body temperature when placed into a cold 
room, show increased anxiety-like behavior in the zero maze, and are hyper-sensitive to seizures 
induced by pentylenetetrazole, a GABAA receptor antagonist.
14,15
 PAM is among a small number 
of enzymes that require copper for their enzymatic function,
16-19
 and behavioral deficits similar 
to those observed in PAM
+/-
 mice are observed in WT mice kept on a copper deficient diet.
14
 
These results suggest that haploinsufficiency of PAM and/or dietary copper deficiency affect 
normal physiological function. 
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In this work, we used a MS-based labeling quantitation approach to search for the 
peptides whose productions are sensitive to the lower level of PAM and/or the different copper 
dietary factors. The quantitation results correlated the peptide level changes to the observed 
behavior of mice under different manipulations of PAM and dietary copper levels. In addition, 
our quantitation results also correlated with this insight that PAM as a secretory granule 
membrane protein have other functions besides catalysing peptide amidation.
20,21
  
3.3  Experimental 
3.3.1 Animals 
Male PAM
+/-
 mice (back-crossed more than 15 generations into C57BL/6J mice) were 
mated with WT female C57BL/6J mice Jackson Laboratory (Bar Harbor, ME); weanlings were 
genotyped as described.
15
 All protocols conformed to University of Connecticut Health Center 
Animal Care Committee guidelines. Dietary copper manipulations were carried out as 
described.
14,15
 WT and PAM
+/-
 mice were made copper deficient by keeping them on a copper 
deficient diet (Harlan Teklad TD80388) with reverse osmosis treated water for 9-10 weeks. 
Copper-supplemented mice were provided with Harlan Teklad control diet #2018 or normal 
mouse chow and deionized reverse osmosis treated water supplemented with 300 ppm 
CuSO4·5H20 (70 ppm Cu) for 14-16 days. Control mice were provided with normal mouse chow 
or Harlan Teklad control diet #2018 and deionized, reverse osmosis treated water.
15
 
3.3.2 Sample Preparation 
Pituitaries were taken from adult WT and PAM
+/-
 mice maintained on a normal, copper-
supplemented diet or a copper-deficient diet. Pools of 2-4 pituitaries were homogenized into 100 
L/pituitary freshly made ice cold acidified acetone (acetone:H2O:HCl=40:6:1, v/v/v) using a 
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ground glass homogenizer and pestle. The homogenizer was rinsed with an additional 100 
L/pituitary of the same solution. Following centrifugation at 3000 rpm for 90 min, supernatants 
were transferred to a new glass tube and subjected to vacuum centrifugation for 90 min to 
remove acetone; the remaining sample was frozen and lyophilized overnight. For analysis, the 
lyophilized samples were dissolved into 2% acetonitrile aqueous solution with 0.1% FA and 
0.01% TFA (20 L/pituitary). Samples were grouped based on the isotopic chemical labels they 
would receive. Because the limited biological samples did not allow the combination 
comparisons for the genotype and diet effects, a loop design for labeling that is common in 
microarray experiments was used as shown in Figure 3.1.A. Horizontal comparison reveals the 
effect of genetic manipulation of PAM, and vertical comparison reveals the effect of copper diet 
on peptides in mouse pituitary. The interaction effects of the genotype and diet were investigated 
through statistical test described later.  
3.3.3 Labeling Reaction 
The labelling reaction was performed as described previously.
5
 The sample solution was 
adjusted to pH 9 with 1M phosphate buffer and 1M NaOH. The control (e.g. WT on a normal 
diet) and the experimental (e.g. PAM
+/-
 on a normal diet) samples were labeled with 5 L of 2M 
light form (SA-H) and heavy form (SA-D) of succinic anhydride (SA) in dimethyl sulfoxide 
(DMSO), respectively. The reagents were mixed well by vortex, and centrifuged followed by the 
incubation for 10 min at room temperature. After incubation, the addition of NaOH for adjusting 
the sample solutions to pH 9 and succinic anhydride for labeling was repeated 4 times. The 
remaining SA was quenched by 20 L of 2.5 M glycine for 40 min at room temperature. The 
labelled control and experimental samples were then combined, followed by adjustment to pH 9. 
10 L of 2 M hydroxylamine solution was added before the mixture reacted at room temperature 
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for 30 min. Following all the reactions, the combined sample was desalted and pre-concentrated 
by using PepClean C18 spin column (Pierce, Rockford, IL). The solvent of the eluent from the 
spin column was evaporated in a SpeedVac (Thermo Electron Co.) and the labeled peptides were 
reconstituted into 2% acetonitrile aqueous solution with 0.1% FA and 0.01% TFA.  
3.3.4 Mass Spectrometry  
The samples after labeling were analyzed with Ultraflex II MALDI-TOF/TOF MS 
(Bruker Daltonics, Bremen, Germany) in the mass range of 600-5000 Da. Specifically, 1 L of 
samples mixed with 1L of 10 mg/mL -cyano-4-hydroxycinnamic acid (-CHCA) in 70% 
acetonitrile aqueous solution containing 0.1% FA and 0.01% TFA was spotted onto a gold 
MALDI target. Each sample was spotted on three MALDI sample spots for technical replicates. 
The spectra obtained with a total of 500 laser shots were summed. Since neuropeptides in mouse 
pituitary have been well characterized, peptide identification was achieved by matching its 
parent ion mass before labeling within 20 ppm of the theoretical mass of mouse pituitary peptide 
previously reported.
22,23
 SA-based isotopic labeling introduced a mass difference of 4 Da 
between the light- and heavy-labeled samples in MALDI-TOF MS analysis. For each peptide, 
quantitation was performed by calculating the peak intensity ratio of the light over heavy forms 
of this peptide. Eight biological replicates were used for study the peptides in WT mice versus 
PAM
+/-
 mice on a normal diet, and four biological replicates for the Cu dietary factor effect. 
3.3.5 Statistical Tests  
Statistical tests with the technical and biological replicates were performed as previously 
described.
5
 Basically, a two-stage mixed model commonly used in microarray analysis was 
applied here. In the first stage, the general differences between MS runs composed of labeling 
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and treatment combinations were removed. The second stage involved a mixed model that was 
fitted to each peptide in terms of genotype, diet, or the interaction between genotype and diet. 
Although the limited samples did not allow us to label for the comparison of all the combinations 
in terms of genotype and diet, this mixed model offered the possibility to investigate the 
interaction between genotype and diet.   
3.4 Results and Discussions 
3.4.1 Succinic Anhydride Based Labeling Quantitation with MALDI-TOF MS 
MALDI-TOF MS has been successfully applied to labeling quantitation studies of 
peptides in mouse pituitary.
3
 Compared to ESI, MALDI-TOF MS simplified the peptide profiles 
with only singly charged peptides (Figure 3.1.B).
24
 In this study, -CHCA was used as matrix to 
provide homogenous distribution of peptides on the sample spots. The instrument parameters 
stayed the same through the analysis on all the sample spots for reproducible results. Only 
spectra with similar peptide profiles over a threshold of 1000 counts were summed to reflect the 
peptide relative levels. Although many reagents are available,
3,5,25-27
 we used succinic anhydride 
for labeling quantitation in this study because of it is a stable and commercially available reagent. 
Although peptides labeled with succinic anhydride showed slight isotopic shifts in their elution 
time during LC separation, it is not a problem in the direct MALDI-TOF MS analysis here. Since 
the mass difference between light and heavy forms of succinic anhydride is about 4 Da, the 
singly labeled peptides in the control and experimental samples appear as a pair of peaks 
separated by 4 Da in the mass spectra (Figure 3.1.C and D).  
In the pituitaries of mice under different manipulations, we observed a large portion of 
peptides derived from proopiomelanocortin (POMC) and several common peptides from 
88 
 
provasopressin and chromogranins. For quantitation purpose, we did not include the peptides 
observed at the MS detection limit because the technical errors may overwhelm the biological 
differences in that case. We also observed some peptides whose masses don’t correspond to any 
previously identified peptides, but none of these peptides showed significant changes. Therefore, 
they are not included in the list either. Not all the peptides change with the same trend for 
different genotypes and/or copper dietary factors, which indicates a complicated peptide 
processing pathway. 
3.4.2 Genetic Effect of PAM on Peptide Amidation  
PAM plays an important role in peptide amidation. Elimination of the PAM gene 
prevents the formation of amidated peptides and is lethal in both Drosophila
11
 and mouse.
12
 
PAM
+/-
 mice, with lower PAM activity than WT mice, survive to adulthood and reproduce,
13
 but 
exhibit a variety of deficits. Consistent with these behavior deficits, our results showed that 
several amidated peptides, including diAc--MSH, -MSH, and JP, have significant level 
changes (p<0.05) due to the haploinsufficiency of PAM regardless of their diet (Table 3.1). 
Interestingly, these peptides appeared to be in higher levels in PAM
+/-
 mice than that seen in WT 
mice. Since PAM is the only enzyme known to be responsible for peptide amidation in mammals 
so far, the increase of amidated diAc--MSH, -MSH, and JP in the PAM+/- mice indicates that 
PAM has more functions besides catalyzing -amidation.  
It has been reported that PAM causes gene expression change by relaying information 
from secretory granules to the nucleus.
21
 The transcripts of aquaporin 1 (Aqp1) and secretory 
leukocyte peptidase inhibitor (Slpi) were reduced 12-fold and 6.6-fold in PAM
+/-
 compared to 
WT mouse pituitary.
21
 Aqp1 is localized to the large dense-core vesicles (LDCVs), and plays an 
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essential role in LDCV biogenesis.
28,29
 The reduction of Aqp1 in AtT-20 cells caused a decrease 
in secretory granule number and several granule protein levels.
28
 These observations indicate that 
PAM
+/-
 mice with decreased Aqp1 may have an impaired regulated secretory pathway. On the 
other hand, Slpi inhibits elastase, cathepsin G, trypsin, and chymotrypsin. Reducing Slpi may 
contribute to the increase in POMC processing. Although there is no direct evidence, it has been 
reported that pituitary cells overexpressing PAM had a decrease in POMC processing.
30
 
Therefore, although the PAM levels are reduced, the increase in PAM substrates and decrease in 
the release of amidated products would still result in the accumulation of amidated peptides in 
mouse pituitary as long as PAM is present. In addition, our results provided the direct evidence 
that -MSH and JP increased in the PAM+/- mice. This was previously indirectly showed by two 
separated studies. One study showed that there was no detectable differences in the ratios of 
amidated -MSH to ACTH (1–39) and amidated JP to ACTH (1–39) were observed with RIAs 
in adult PAM
+/-
 mouse pituitary,
12
 while the other indicated that ATCH was possible to increase 
with decreased PAM by showing increased expression of PAM caused decreased 
immunofluorescent staining for ACTH.
31
 
Most of the observed peptides did not show significant changes in PAM
+/-
 mice. Besides 
diAc--MSH, -MSH, and JP, we also observed other peptides derived from POMC with or 
without C-terminal amidation. There was a large variation in the relative levels of these peptides 
among the biological replicates. Also, these peptides have shown been present among many 
related forms in mouse pituitary.
32
 For example, multiple CLIP fragments and phosphorylated 
CLIP were detected in mouse pituitary.
32 
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3.4.3 Copper Dietary Effect on Peptide Amidation 
PAM is among a small number of enzymes that require copper for their enzymatic 
function,
16-19
 and behavior deficits similar to those observed in PAM
+/-
 mice were observed in 
WT mice kept on a copper deficient diet.
14
 Also, dietary copper supplementation was reported to 
reverse these behavior deficits in PAM
+/-
 mice.
14
 In the peptidomics study of mice on a different 
copper diet, we observed fewer peaks (14 observations/peptide) in the samples on a copper 
deficient diet, and similar number of peaks (64 observations/peptide) in the samples on a copper 
supplemental diet compared to those from the normal samples (77 observations/peptide) after 
labeling. The statistical results from these data are shown in Table 3.1. The reasons for fewer 
observations of labeled peptides in mice on a copper deficient diet need further investigation. 
Within the comparable peptide profiles, -MSH was significantly decreased in the 
copper supplemental mice compared to normal diet mice regardless of genotypes (Table 3.1). 
For PAM
+/-
 mice, this result may indicate the decrease of -MSH induced by copper 
supplemental diet compensated the increase of -MSH caused by genetic manipulation, and thus 
the effects of genotype and dietary factor interacted and brought the -MSH level to that in WT 
mice on a normal diet. For WT mice, the decrease of -MSH caused by copper supplementation 
may indicate that copper concentrations in excess of an optimum value could also lead to a 
decrease in amidation activity.
9
 
Although chromogranin A (243-253) is a non-amidated peptide, we observed that its 
level changes with the dietary copper amount (Table 3.1). Both more and less copper in the diet 
could induce a decrease of chromogranin A (243-253). In a previous study, -lipotropin 
(MH
+
theor.=4438.81), another non-amidated peptide derived from POMC was found to 
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significantly decrease in Atp7a knock-out mice relative to WT mice.
3
 Atp7a transports copper 
from the cytosol into the lumen of the secretory pathway, and thus a defect in ATP7A results in a 
lack of copper.
3
 Due to the different instrumentation platforms, we observed different sets of 
peptides. However, both of our results suggested that copper levels may affect the productions of 
non-amidated peptides as well as amidated peptides. 
3.5 Conclusions 
In summary, we used a MS-based labeling quantitation approach to investigate the 
peptide production in PAM
+/-
 mice on different copper diets. Our results showed that diAc--
MSH, -MSH, and JP, common peptides derived from POMC, were significantly increased in 
PAM
+/-
 mice compared to WT mice. Copper supplemental samples showed a compensate trend 
to bring the levels of -MSH increased in PAM+/- mice back to the normal levels as in WT mice. 
Our results supported the PAM multiple functions besides catalyzing peptide amidation, and 
demonstrated that genotype and dietary effect interacted, and their level changes correlated with 
the mouse behavior observed under different manipulations.
14,15
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3.6 Figures 
 
 
Figure 3.1. Experimental design and mass spectrometry results for analyzing peptide level 
changes regulated by genotypes and copper (Cu) dietary factors. Wildtype (WT) and PAM 
heterozygous (PAM
+/-
) mice on a Cu normal, Cu deficient, or Cu supplemental diet were 
grouped for labeling quantitation. (A). A loop design was used to compare the peptide level 
changes between WT and PAM
+/- 
on a certain Cu diet. (B). Peptide profiles in the mass range of 
700-3000 Da after labeling obtained with MALDI-TOF MS. The most abundant peaks were 
assigned to isotopically labeled arginine-vasopressin (AVP). The insert is the zoom-in mass 
spectrum in the mass range of 1700-2200 Da. (C). A representative peak pairs for isotopically 
labeled -MSH in WT vs. PAM+/- on a normal diet. The peak at 1764.78 is -MSH labeled with 
light form of SA (SA-H) in WT mice, and the peak at 1768.77 is the same peptide labeled with 
heavy form of SA (SA-D) in PAM
+/-
 mice. The intensity ratio of the peak pair indicates relative 
level difference of -MSH in WT vs. PAM+/-. (D). Another example (joining peptide) in the 
same samples (WT, normal diet vs. PAM
+/-
, normal diet). 
9
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4.1 Notes and Acknowledgments 
Following the studies on mature peptides in the pituitary of mice under different 
genotypes on different copper diets, we continue to examine the corresponding immature 
peptides under these manipulations. This work is adapted from an in-preparation article entitled 
“Probing the production of amidated peptides following genetic and dietary copper 
manipulations”, co-authored with Danielle Bousquet-Moore and Richard E. Mains in Betty A. 
Eipper’s group at University of Connecticut, and Suresh P. Annangudi in Jonathan V. Sweedler’s 
group at University of Illinois at Urbana-Champaign. Danielle Bousquet-Moore prepared and 
dissected the animals, and Suresh P. Annangudi did the initial studies on MS-related section. I 
would also like to acknowledge Betty A. Eipper, Richard E. Mains, and Jonathan V. Sweedler 
for insights and contributions on this work, and Stephanie C. Baker for the final editing of the 
submitted manuscript. This work is supported by National Science Foundation (NSF) through 
CHE-0526692 and National Institutes of Health (NIH) through DA018310 and DK32949.      
4.2 Introduction 
Neuropeptide production typically involves endoproteolytic cleavage of prohormones by 
prohormone convertases followed by exoproteolytic cleavage by carboxypeptidase E. As the 
prohormone and its cleaved products traverse the secretory pathway, various post-translational 
modifications occur. One important modification is -amidation, a reaction catalyzed by 
peptidylglycine -amidating monooxygenase (PAM).1,2 Over half of the biologically active 
peptides are amidated.
3
 The presence of an amide group at the C-terminus of a peptide often 
increases its affinity to its receptor and extends peptide half-life. Elimination of the PAM gene 
prevents the formation of amidated peptides and is lethal in both Drosophila
4
 and mouse.
2
 PAM 
100 
 
heterozygous (PAM
+/-
) mice, with lower PAM activity than wildtype (WT) mice, survive to 
adulthood and reproduce,
3
 but exhibit a variety of deficits. For example, PAM
+/-
 mice are unable 
to maintain body temperature when placed into a cold room, show increased anxiety-like 
behavior in the zero maze, and are hyper-sensitive to seizures induced by pentylenetetrazole, a 
GABAA receptor antagonist.
5,6
 PAM is among a small number of enzymes that require copper 
for their enzymatic function,
7-10
 and behavior deficits similar to those observed in PAM
+/-
 mice 
are observed in WT mice kept on a copper deficient diet.
5
 These results suggest that 
haploinsufficiency of PAM and/or dietary copper deficiency affect normal physiological function. 
PAM has two enzymatic domains, peptidylglycine--hydroxylating monooxygenase 
(PHM) and peptidyl--hydroxyglycine -amidating lyase (PAL). PHM converts glycine-
extended peptides into hydroxyglycine-extended peptides by using molecular oxygen to 
hydroxylate the -carbon of the C-terminal glycine in a copper and ascorbate dependent reaction. 
The hydroxyglycine-extended peptide is then converted into the corresponding amidated peptide 
and glyoxylate by PAL.
11,12
 Although several glycine-extended peptides (e.g. TRH-Gly
5,13,14
 and 
gastrin-Gly
15,16
) have been characterized using radioimmunoassays, they have not been studied 
systematically. Here we studied the effects of PAM haploinsufficiency and dietary copper 
deficiency on levels of several glycine-extended and hydroxyglycine-extended peptides in the 
mouse pituitary.    
To better understand how PAM haploinsufficiency and dietary copper deficiency affect 
neuropeptide production, a neuropeptidomics study was performed. Liquid Chromatography-
Mass Spectrometry (LC-MS), which provides both qualitative and quantitative information, 
allows sensitive and accurate determination of neuropeptide forms.
17-20
 We used LC-MS to study 
glycine-extended and hydroxyglycine-extended peptides in the mouse pituitary. The endogenous 
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intermediates are present at a much lower level than their fully-processed, amidated counterparts, 
making their identification and quantitation challenging. We employed both matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) MS and electrospray ionization ion-trap 
(ESI-IT) MS following LC separation. Synthetic glycine-extended and hydroxyglycine-extended 
peptides aided in the characterization of the labile intermediates.  
After identification, levels of glycine-extended and hydroxyglycine-extended peptides 
were compared to those of amidated product using MS-based peak intensities, and differences 
were correlated to genetic and/or dietary manipulations. The standard approach of isotopically 
labeling peptides requires multiple sample processing steps, which cause reductions of peptides 
already at low levels to the point below MS detection limit.
20
 In addition, labeling approaches 
tend to work best when the level of the peptides being examined are similar. Instead, we used a 
label-free approach to provide relative levels of the partially processed peptides.
21,22
 Our results 
demonstrate that glycine-extended peptides accumulate when PAM levels are low and when 
copper availability is limited, and improve our understanding of the two-step -amidation 
reaction catalyzed by PHM and PAL.  
4.3 Experimental 
4.3.1 Chemicals 
Synthetic ACTH(1-13)-Gly [ACTH(1-14)] (AnaSpec, Fremont, CA) was converted into 
ACTH(1-13)-Gly-OH using purified PHM. The 1.0 mL reaction mixture contained 1.0 M 
CuSO4, 0.5 mM ascorbic acid, 100 M peptide, 12 g PHMccQ170A, and 0.09 mg/mL bovine 
liver catalase (Sigma) in 150 mM NaMES, pH 5.0 and the reaction was allowed to proceed for 5 
h at 37
o
C. The reaction was stopped by adding an equal volume of 0.1% trifluoroacetic acid 
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(TFA). The peptide was adsorbed to a SepPak C18 Bondapak cartridge, which was then washed 
with 0.1% TFA and eluted with 80% acetonitrile in 0.1% TFA. Fractions containing peptide 
were pooled based on A280 and lyophilized. The HPLC grade solvents such as water and 
acetonitrile with 0.1% formic acid (FA) and 0.01% TFA were purchased from Fisher Scientific 
(Pittsburgh, PA). α-cyano-4-hydroxycinnamic acid (α-CHCA) was from Sigma-Aldrich (St. 
Louis, MO). 
4.3.2 Animals 
Adult male PAM
+/-
 mice were used for all reported experiments. Male PAM
+/-
 mice 
(back-crossed more than 15 generations into C57BL/6J mice) were mated with WT female 
C57BL/6J mice Jackson Laboratory (Bar Harbor, ME); weanlings were genotyped as described.
6
 
All protocols conformed to University of Connecticut Health Center Animal Care Committee 
guidelines. Dietary copper manipulations were carried out as previously described.
5,6
 WT and 
PAM
+/-
 mice were made copper deficient by keeping them on a copper deficient diet (Harlan 
Teklad TD80388) with reverse osmosis treated water for 9-10 weeks. Copper-supplemented 
mice were provided with Harlan Teklad control diet #2018 or normal mouse chow and deionized 
reverse osmosis treated water supplemented with 300 ppm CuSO4•5H20 (70 ppm Cu) for 14-16 
days. Control mice were provided with normal mouse chow or Harlan Teklad control diet #2018 
and deionized, reverse osmosis treated water.
6
 
4.3.3 Sample Preparation 
Pituitaries harvested from adult male mice were pooled into groups of 2-4 pituitaries, 
homogenized into 100 l/pituitary freshly made ice cold acidified acetone 
(acetone:H2O:HCl=40:6:1, v/v/v) using a ground glass homogenizer and pestle. The 
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homogenizer was rinsed with an additional 100 L/pituitary of the same solution. Following 
centrifugation at 3000 rpm for 90 min, supernatants were transferred to a new glass tube and 
subjected to vacuum centrifugation for 90 min to remove the acetone; the remaining sample was 
frozen and lyophilized overnight. For analysis, the lyophilized samples were dissolved into 2% 
acetonitrile aqueous solution with 0.1% FA and 0.01% TFA (20 L/pituitary). Eight separate 
sets of WT and PAM
+/-
 mice kept on a normal diet were analyzed. Three separate sets of PAM
+/-
 
mice kept on a normal or copper supplemented diet were compared, and three separate sets of 
WT and PAM
+/-
 mice kept on a normal or copper deficient diet were compared. 
4.3.4 LC-MS analysis 
Endogenous glycine-extended peptides were identified by both signature fragment ion 
mass matching and elution order as well as the widely used MS/MS matching with CapLC 
(Micromass, Manchester, UK) coupled to HCTultra ESI-IT MS and MS/MS (Bruker Daltonics, 
Bremen, Germany). Endogenous hydroxyglycine-extended peptides were identified by parent 
ion mass matching, parent ion instability, and elution order with CapLC (Micromass, Manchester, 
UK) coupled to Ultraflex II MALDI-TOF/TOF MS (Bruker Daltonics, Bremen, Germany).  
Peptide standards consisting of glycine-extended and hydroxyglycine-extended forms 
were used to assist the identification of partially processed peptides by providing information on 
signature fragment ions and elution order; here, 2 L of 1 M ACTH(1-13)-Gly and 2 L of 10 
M ACTH(1-13)-Gly-OH solutions were added to 6 L pituitary extract from WT mice. The 
mouse pituitary extracts or the spiked samples were separated by CapLC with Solvent A (95% 
water, 5% acetonitrile, 0.1% FA, and 0.01% TFA), and Solvent B (5% water, 95% acetonitrile, 
0.1% FA, and 0.01% TFA). The 45-min gradient was programed from 3% B to 20% B in 5 min, 
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to 40% B in another 19 min, continued to 80% B in 7 min, and stayed at 80% B for 3 min before 
ramping back to 3% B. The fractions were immediately subjected to HCTultra ESI-IT MS or 
Ultraflex II MALDI-TOF/TOF MS, and follow-up tandem MS analyses. The fragment ion mass 
matches were considered positive when within 0.2 Da from ESI-IT MS/MS analysis, and the 
parent ion mass matches when within 5 ppm from MALDI-TOF MS analysis. 
To test the stability of hydroxyglycine-extended peptide, 0.5 L of 100 M ACTH(1-13)-
Gly-OH aqueous solution with 0.1% FA and 0.01% TFA (pH~3) was deposited on a steel 
MALDI plate with 0.5 L of 10 mg/mL α-Cyano-4-hydroxycinnamic acid (α-CHCA) in 
acetonitrile aqueous solution (ACN/H2O=70/30, v/v). The air-dried sample spot was analyzed by 
linear and reflectron modes of MALDI-TOF/TOF MS sequentially. The laser power was 
consistent during the acquisition, and a total of 500 laser shots were summed for each spectrum. 
In addition, 50L of 100 M ACTH(1-13)-Gly-OH in acidic aqueous solution was mixed with 
50 L of acetonitrile for ESI-IT MS analysis with direct infusion. The m/z of doubly charged 
ACTH(1-13)-Gly-OH and its amidated form, ACTH(1-13)-NH2, were used as parent ions to be 
first isolated and then fragmented. The most intense fragment ion in this first-step fragmentation 
was again isolated and then further fragmented. 
The identified peptides were quantified by a label-free MS-based approach using LC-
MALDI-TOF MS.
21,22
 Briefly, 5L samples prepared from the pituitaries of mice of different 
genotypes or mice maintained on different diets were separated using the CapLC system 
described above. A total of 24 one-minute fractions collected between 20 and 45 min were 
spotted for MALDI-TOF/TOF MS analysis. α-CHCA (1L of 10 mg/mL) was added to each 
air-dried sample spot. AutoeXcute in Ultraflex II MALDI-TOF/TOF MS was used to 
automatically acquire MS data for each sample in the mass range of 900–2500 Da. To obtain 
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highly reproducible results for quantitative analysis, sets of pituitary extracts prepared from mice 
of different genotypes or mice kept on different dietary regimens were subjected to parallel 
analyses with identical parameters from sample handling to LC-MS analysis. The amidated 
peptides were confirmed by MALDI-TOF/TOF tandem MS, and then used for internal 
calibration. The peak annotation to glycine-extended or hydroxyglycine-extended peptides was 
made by parent ion mass matches within 5 ppm and via peak elution order. Intensities of peaks 
annotated to one peptide but eluted in several consecutive fractions were summed after 
normalization. The relative amounts of partially processed peptides compared to their amidated 
forms were indicated by the ratio of their corresponding intensities (glycine-extended 
peptide/amidated peptide or hydroxyglycine-extended peptide/amidated peptide) within the same 
sample.  
To minimize the effect of experimental error, the comparison of glycine-extended peptide 
relative levels under different manipulations was conducted within a pair of samples which were 
prepared and analyzed at the same time. For example, a ratio for WT to PAM
+/-
 mice on a normal 
diet was calculated by dividing the ratio of glycine-extended peptide to amidated peptide for WT 
(Group 1) by the same ratio for PAM
+/- 
(Group 2). Statistical tests were then performed with this 
2
nd
 ratio (Group 1/Group 2) across biological replicate pairs analyzed at different times. 
Additionally, several hydroxyglycine-extended peptides were not consistently detected because 
of dynamic range/detection issues. In such cases, the amount of peptide present was less than MS 
detection limit, and the detection limit values (e.g. hydroxyglycine-extended peptide/amidated 
peptide ≈ 0.0002 in average) were used to allow such runs to be included. 
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4.4 Results 
4.4.1 Identification of Amidated Peptides and Their Glycine-extended Precursors 
A total of 12 amidated peptides with/without other PTMs such as N-terminal acetylation 
were identified in adult male mouse pituitary extracts with MS/MS (Table 4.1). Although 
production of each amidated peptide must proceed through glycine-extended and 
hydroxyglycine-extended intermediates, few of these intermediates could be detected. While the 
neuropeptides in the mouse pituitary have been well characterized,
23-25
 these intermediates are 
present at low levels and most have not been reported with MS detection. Characterization of 
these amidation intermediates is challenging because of their low levels compared to the fully 
processed peptides, combined with MS detection limits and dynamic range. Among several 
observed amidation intermediates, glycine-extended joining peptide (JP-Gly) was identified with 
good sequence coverage via ESI-IT MS/MS (Figure 4.1.B). 
For peptides that did not produce full coverage of fragment ions with MS/MS analysis, 
their identifications were based on their parent ions, signature fragment ions, and elution order 
relative to the amidated forms. We determined this information for amidated, glycine-extended, 
and hydroxyglycine-extended synthetic ACTH(1-13) before using this information for 
endogenous peptide identification. The signature fragment ions for glycine-extended peptides 
reflect the presence of a C-terminal glycine instead of a C-terminal amide. Therefore, the 
glycine-extended peptide is expected to consist of the same set of b ions, and a set of singly 
charged y ions with mass difference of ~58 Da (C2H5NO2 minus NH3) compared to its amidated 
product. These predictions were well supported by the fragment ions generated from synthetic 
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ACTH(1-13)-Gly vs. synthetic ACTH(1-13)-NH2 and from endogenous JP-Gly vs. JP-NH2 
(Figure 4.1).  
With signature fragment ion assignments, we identified endogenous glycine-extended 
forms of oxytocin (OT-Gly) and arginine-vasopressin (AVP-Gly) with LC-ESI-IT MS/MS. As 
shown in Figure 4.2.A, identical b6-8 ions between OT-Gly and OT-NH2, together with the 
singly charged y ions and doubly charged (M-17) ions of OT-Gly with 58 and 29 Da mass 
difference from those of OT-NH2, suggested the assignment of OT-Gly. The disulfide bond 
between Cysteine 1 and Cysteine 6 hindered cleavages to form smaller b ions and larger y ions. 
In addition, the identities of these glycine-extended peptides were confirmed by their LC elution 
times in comparison to those of synthetic peptides. ACTH(1-13)-NH2, ACTH(1-13)-Gly-OH, 
and ACTH(1-13)-Gly showed increasingly longer retention times on the reversed-phase column. 
Accordingly, we observed JP-Gly, AVP-Gly, and OT-Gly elute after the corresponding amidated 
peptides. 
4.4.2 Quantification of Glycine-extended Precursors vs. Amidated Peptide 
There are several approaches for comparing the relative levels of peptides, including 
stable isotope labeling and label-free approaches.
19-22,26
 We used a label-free LC-MALDI-TOF 
MS approach because it requires less sample processing and is well suited to characterizing 
peptides present at levels near the MS detection limit. Although neither form of oxytocin was 
observed by LC-MALDI-TOF MS, this technique provided enough sensitivity and resolution for 
us to quantify JP-Gly and AVP-Gly relative to their amidated forms. Automatic MS acquisition 
provides similar peptide profiles for samples from different groups. As expected, in WT mice 
kept on their normal diet, levels of JP-Gly and AVP-Gly were very low when compared to levels 
of JP-NH2 and AVP-NH2, respectively. For example, JP-Gly levels were 100-1000 fold below 
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JP-NH2 levels and AVP-Gly levels were 1000-2000 fold below AVP- NH2 levels. This same 
ratio was calculated for PAM
+/- 
mice. If the level of PAM present in corticotropes or in the 
hypothalamic neurons that produce AVP is limiting, one would expect to see an increase in the 
ratio of glycine-extended to amidated peptide in the PAM
+/-
 mice. As shown in Figure 4.3, the 
JP-Gly/JP-NH2 ratio for WT mice is significantly smaller (p<0.05) than the same ratio for 
PAM
+/-
 mice. The effect of PAM haploinsufficiency on the AVP-Gly/AVP-NH2 ratio was more 
dramatic, with a greater than 5-fold drop in this ratio (p<0.0005). 
Since the catalytic activity of PAM is dependent on copper, we next asked whether the 
ratio of glycine-extended to amidated peptide were altered by copper deficiency in WT or 
PAM
+/-
 mice. If lack of copper limits the ability of PAM to catalyze this reaction, one would 
expect the glycine-extended to amidated peptide ratio to be increased by copper deficiency. In 
PAM
+/-
 mice, this is exactly what was seen for JP: JP-Gly accumulated when these mice were 
copper deficient (p<0.05). For AVP-Gly, a trend towards accumulation of the glycine-extended 
peptide was observed (p<0.1) in the PAM
+/-
 mice. For WT mice, a trend towards accumulation 
of JP-Gly was observed in copper deficiency (p<0.1), but there was no evidence for 
accumulation of AVP-Gly in copper deficiency. Copper supplementation did not reduce the 
accumulation of JP-Gly or AVP-Gly observed in PAM
+/-
 mice, although there is a large variation 
for AVP-Gly. Overall, both lower levels of PAM and a copper deficient diet induced 
accumulation of JP-Gly while AVP-Gly accumulation was increased only by a reduction in PAM 
levels.  
4.4.3 Identification of the Hydroxyglycine-extended Intermediates 
Although test tube studies and metabolic labeling revealed the two-step nature of the 
amidation reaction,
23
 hydroxyglycine-extended peptides have not yet been identified in tissue. 
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Their presumed low abundance compared to the amidated forms makes measurement of 
hydroxyglycine-extended peptides challenging. In addition, it is known that hydroxyglycine-
extended peptides are unstable in basic aqueous solutions, generating amidated peptide non-
enzymatically.
27
 Our data indicate that hydroxyglycine-extended intermediates are not stable in 
the gas phase during MS measurement and decompose to form amidated peptide. During 
MALDI-TOF MS analysis, ACTH(1-13)-Gly-OH produced from ACTH(1-13)-Gly using 
purified PHM was largely converted into ACTH(1-13)-NH2 (Figure 4.4.A).  
We confirmed that ACTH(1-13)-Gly-OH decomposed during MS measurement by using 
the reflectron mode of MALDI-TOF MS. Just as with the -carboxyglutamate residue in a 
peptide,
28
 the ion lasts long enough to enter the field-free region and then fragments. In the linear 
mode, the peptide fragments reach the detector as a single peak with the hydroxyglycine-
extended peptides. However, during reflectron operation, the decomposition products are 
separated well from the hydroxyglycine-extended peptides and dominate the MS detection. 
Therefore, we observed a greatly reduced relative intensity of ACTH(1-13)-Gly-OH compared to 
ACTH(1-13)-NH2 in the reflectron mode compared to the linear mode, which indicates that 
ACTH(1-13)-Gly-OH is converted into ACTH(1-13)-NH2 during MS analysis (Figure 4.4.A).  
We further investigated the nature of this instability by using ESI-IT MS/MS, where we 
isolated the parent ions of either ACTH(1-13)-NH2 or ACTH(1-13)-Gly-OH, and then carried 
out corresponding MS2 and/or MS3 analysis. After conducting MS2 on the isolated ACTH(1-
13)-Gly-OH parent ion, we observed a single peak corresponding to ACTH(1-13)-NH2. This 
peak produces the same fragment ions to the ones produced from MS2 of isolated ACTH(1-13)-
NH2 (Figure 4.4.B). These observations support the idea that hydroxyglycine-extended peptides 
are detected with the corresponding amidated form in the same MS scan because of their 
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decomposition. Using a similar criterion (a peak that decomposes into the amidated form), the 
expected elution order, and a parent ion mass match within 5 ppm by MALDI-TOF MS, we 
confirmed the identity of hydroxyglycine-extended JP (JP-Gly-OH) from mouse pituitary.  
4.4.4 Effect of PAM Haploinsufficiency on ydroxyglycine-extended Peptide 
Levels 
The ability to detect both JP-Gly and JP-Gly-OH in tissue extracts makes it possible to 
determine the rate-limiting step in producing JP-NH2 by this two-step reaction. Kinetic studies 
with purified PHM and PAL revealed a higher affinity of PHM for its peptide substrate and a 
higher turnover number for PAL.
29
 In WT mice on a normal diet, JP-Gly-OH levels were 
generally at or below the MS detection limit and were approximately 5000-fold below the level 
of JP-NH2 (Figure 4.5.A). When peptide levels were below the MS detection limit, an average 
ratio of hydroxyglycine-extended peptide to amidated peptide at the detection limit was used to 
allow all LC-MS runs to be included. In PAM
+/- 
mice, levels of JP-Gly-OH were often above the 
detection limit and the ratio of JP-Gly-OH to JP-NH2 was higher than observed in WT mice 
(p<0.1) (Figure 4.5.A), suggesting that the amount of PAL had become limiting. Levels of JP-
Gly-OH were approximately 20-fold lower than levels of JP-Gly in WT mice (p<0.1), and about 
5-fold lower in PAM
+/-
 mice (p<0.05), indicating that the monooxygenase reaction is a slower 
step in peptide amidation (Figure 4.5.B).   
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4.5 Discussions 
4.5.1 Detecting Amidation Reaction Intermediates 
We identified JP-Gly, derived from pro-opiomelanocortin (POMC), AVP-Gly, from pro-
vasopressin-neurophysin, and OT-Gly, from pro-oxytocin-neurophysin. Other POMC-derived 
peptides such as -MSH were observed only in mature forms with C-terminal amidation, mono- 
or di-N-terminal acetylation, and/or methionine oxidation.  JP, an acidic peptide located between 
ɣ-MSH and ACTH in POMC, is a normal end-product of POMC processing and has been used 
as an indicator of corticotrope function, POMC processing and amidation.
30,31
 AVP and OT are 
synthesized in the hypothalamus, transported to the neural lobe of the pituitary, and stored there 
until released. AVP released from the pituitary plays a key role in regulating plasma 
osmolality.
32
 OT is best known for its roles in female reproduction, social recognition, anxiety, 
and maternal behaviour.
33
  
Several factors may have contributed to our inability to detect more glycine-extended 
peptides such as -MSH-Gly. First, the intrinsic low levels compared to their amidated 
counterparts with ion suppression render most glycine-extended peptide ions below the MS 
detection limit. Second, the -MSH series of peptides are better substrates for PAM than JP, OT, 
and AVP, facilitating more complete -amidation. Test tube assays demonstrate that neutral 
hydrophobic residues such as valine (Val) are more effective PAM substrates than charged 
residues such as aspartate (Asp) or glutamate (Glu); peptides terminating with Gly-Gly or Pro-
Gly are not especially effective PAM substrates either.
34
 -MSH-related peptides, which 
terminate with Val-Gly, are better substrates for PAM, than JP-related peptides, which terminate 
with Glu-Gly, or OT and AVP, both of which terminate with Gly-Gly. Third, many of the 
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undetected partially processed peptides have multiple other PTMs,
35
 perhaps the temporal 
formation of the various modifications determines whether specific partially processed peptides 
can be detected. 
4.5.2 MS-based Label-free Quantitation 
It is also worth noting that most quantitative studies focus on the same peptides in 
multiple samples following different manipulations. Here, on the other hand, we investigated 
how the relative levels of two related but distinct peptides changed with genetic and dietary 
manipulations using a label-free LC-MALDI TOF/TOF MS approach. Although the two related 
peptides have similar amino acid compositions, they may have different ionization efficiencies 
due to their distinct chemical structures; therefore, the ratio of partially processed peptides to 
amidated peptides may not reflect the exact relative amount of the two peptides. However, the 
ionization efficiency factors for those peptides cancel out when we compare the ratios of two 
related peptides from samples following different manipulations. Therefore, the ratio difference 
reflects the relative peptide level changes in response to various manipulations. This approach 
should provide a robust comparison on peptides present at very low levels.  
4.5.3 PAM Haploinsufficiency and Manipulation of Dietary Copper Produce Small 
Changes in Glycine-extended Peptides 
PAM
+/- 
mice exhibit increased anxiety-like behavior and a decreased ability to regulate 
body temperature in a cold room.
5,6
 These deficits observed in PAM
+/-
 mice could reflect 
abnormal levels of many different amidated peptides or diminished levels of PAM protein. 
Recent studies revealed the occurrence of a -secretase-mediated cleavage in the transmembrane 
domain of PAM, releasing a soluble cytosolic fragment of PAM that accumulates in the nucleus 
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and alters gene expression.
36,37
 The ability to quantify peptidyglycine intermediates makes it 
possible to distinguish between these possibilities. 
The LC-MS-based approach used here allowed us to screen peptide content with high 
throughput and sensitivity. When detectable, we found glycine-extended peptides present at 
levels 100-1000 fold below those of their amidated products in WT mice. Based on 
radioimmunoassay data, the TRH-Gly/TRH-NH2 ratio in the CNS is much higher, perhaps 
reflecting the diminished affinity of PHM for substrates terminating with a Pro-Gly 
sequence.
5,13,14
 Previous radioimmunoassay-based studies of secretin and gastrin, major 
gastrointestinal peptides, identified high levels of  secretin-Gly
38
 and gastrin-Gly.
15,16
 In rat 
intestinal extracts, secretin-Gly levels were half those of secretin-NH2; circulating gastrin-
Gly/gastrin-NH2 ratios in humans, pigs, and sheep range from 0.3 to 1.0.
15
 Gastrin-Gly is 
reported to have functions distinct from those of gastrin.
16
 In our study, JP-Gly and AVP-Gly 
were significantly more prevalent in PAM
+/-
 mice than in WT mice, but the glycine-extended 
peptides were still minor components. For most peptides, glycine-extended precursors were not 
detectable with MS. 
In addition, we observed an accumulation of JP-Gly in WT mice on a copper deficient 
diet and enhanced accumulation of JP-Gly in PAM
+/-
 mice on a copper deficient diet. 
Interestingly, copper deficiency led to an accumulation of AVP-Gly in PAM
+/-
 but not in WT 
mice. It is clear that changes in PAM levels and copper levels interact and affect different 
peptides in different ways. A previous study, which utilized immunoassays to distinguish TRH-
NH2 from TRH-Gly, demonstrated increased levels of TRH-Gly in copper deficient WT mice 
with no effect of copper supplementation on TRH-Gly levels in PAM
+/-
 mice.
5
 Similar responses 
were observed for JP-Gly and AVP-Gly in this study. The effects of dietary limitations in copper 
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on the amidation reaction vary substantially for different amidated neuropeptides, perhaps 
reflecting the properties of the prohormone itself or the copper metabolism of that particular cell 
type. 
Although PAM haploinsufficiency and manipulation of dietary copper have the predicted 
effects of JP-Gly and AVP-Gly levels, the amidated versions of these neurpeptides remain much 
more prevalent. It is difficult to see how changes in the levels of amidated vs. glycine-extended 
peptide could account for the phenotypic changes observed in PAM
+/-
 mice or the ability of 
dietary copper supplementation to ameliorate these deficits. Our results suggest that the ability of 
PAM to affect gene expression and copper metabolism play a key role in this response.
5,37
   
4.5.4 Quantification of Hydroxyglycine-extended Peptides 
Production of amidated peptides from their glycine-extended precursors involves 
formation of hydroxyglycine-extended intermediates. This reaction intermediate has been 
identified in test tube assays and by metabolic labeling,
23
 but not in tissue, perhaps reflecting its 
low abundance and intrinsic instability. As early as 1991, Bundgaard et al. reported non-
enzymatic base-catalyzed hydrolysis of hydroxyglycine-extended peptides and their 
derivatives.
39
 Acid- or base- catalyzed deprotonation of the hydroxyl moiety of carbinolamides 
have also been proposed.
40,41
 Here, we showed that the conversion of hydroxyglycine-extended 
peptides to their amidated forms also occurs in the gas phase during MS. We employed this 
conversion as a criterion to aid in our assignment of hydroxyglycine-extended peptides. 
Although more investigation is needed to reveal the decomposition mechanism, we hypothesize 
that the acid-catalyzed decomposition of hydroxyglycine-extended peptides is accelerated by an 
initial decarboxylation step.
28,40
 
115 
 
The fact that the ratio of JP-Gly-OH to JP-Gly in pituitary extracts is substantially less 
than 1 (Figure 4.5.B) supports the hypothesis that PHM is the rate limiting enzyme. Assays of 
purified PAM are consistent with this conclusion; kcat values for PAL are approximately five-
fold higher than kcat values for PHM.
29
 Genes encoding bifunctional PAM appear to have 
evolved from separate genes encoding PHM and PAL.
42
 The remarkable sensitivity of 
hydroxyglycine-extended peptides to their acidic/basic environment may be important in species 
whose genomes encode monofunctional PHM. Examples include Drosophila,
4
 Planaria,
43
 
Calliactis,
44
 and the human parasite Schistosoma mansoni,
45
 where a monofunctional PHM gene 
is not always co-expressed with PAL. Compared to WT mice, PAM
+/-
 mice accumulated JP-Gly-
OH over amidated JP, suggesting that levels of PAL can become limiting. 
4.6 Conclusions 
To summarize, we identified several intermediates of the amidation reaction, including 
JP-Gly, AVP-Gly, OT-Gly, and JP-Gly-OH, and quantified changes in their levels relative to 
their amidated products in mice of different genotypes or mice maintained on different copper 
diets. Mice with reduced levels of PAM accumulated JP-Gly-OH, JP-Gly and AVP-Gly in their 
pituitaries. Copper deficiency had a similar effect on JP-Gly but not AVP-Gly in WT mice, while 
copper deficiency enhanced the accumulation on both JP-Gly and AVP-Gly in PAM
+/-
 mice. The 
lower amount of JP-Gly-OH than that of JP-Gly, independent of genetic manipulations, suggests 
that PHM is rate limiting. PAM
+/-
 mice accumulated JP-Gly-OH over amidated JP to a larger 
extent than WT mice, indicating that levels of PAL can become limiting. A systematic study on 
the stability of hydroxyglycine-extended peptides will provide more insight into the PAL 
catalytic mechanism and -amidation catalyzed by PHM in the absence of PAL.
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4.7 Figures 
 
 
 
 
Figure 4.1. Capillary LC coupled to electrospray ionization ion-trap (LC-ESI-IT) tandem mass 
spectra of amidated (top) and glycine-extended (bottom) forms of (A) synthetic 
adrenocorticotropic hormone (ACTH) (1-13), and (B) endogenous joining peptide (JP). The 
assignment of b- and y-ions matches expected fragments within 0.2 Da. 
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Figure 4.2. Capillary LC coupled to electrospray ionization ion-trap (LC-ESI-IT) tandem mass 
spectra of amidated (top) and glycine-extended (bottom) forms of (A) oxytocin and (B) arginine-
vasopressin. The labeled b and y ions are the signature fragment ions used for their identification. 
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Figure 4.3. Effect of PAM haploinsufficiency and dietary copper on amidation of (A) joining 
peptide (JP) and (B) arginine-vasopressin (AVP). Samples from WT and PAM
+/-
 mice kept on a 
normal, Cu deficient or Cu supplemented diet were analyzed. For each sample, the ratio of 
glycine-extended to amidated peptide was calculated, with higher numbers indicating an 
accumulation of glycine-extended peptide. The effects of haploinsufficiency, Cu deficiency and 
Cu supplementation were assessed by dividing these ratios (Group 1/Group 2); a number 
significantly less than 1 indicates that glycine-extended peptide accumulate to a greater extent in 
Group 2 than in Group 1. N is the number of biological replicate pairs. Error bar, SEM. Student’s 
t-test: ***, p<0.0005; **, p <0.05; *, p < 0.1.  
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Figure 4.4. Conversion of ACTH(1-13)-Gly-OH to its amidated form ACTH(1-13)-NH2 during 
the measurement process when analyzed by (A) MALDI-TOF/TOF MS and (B) ESI-IT MS/MS. 
(A). The table shows the assessment of the amidated and hydroxyglycine-extended ACTH(1-13) 
peaks in MALDI-TOF/TOF MS. (B). With manual ESI-IT tandem MS, ACTH(1-13)-NH2 and 
ACTH(1-13)-Gly-OH were respectively isolated, and then fragmented. The MS2 of ACTH(1-
13)-NH2 matches the MS3 of ACTH(1-13)-Gly-OH. 
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Figure 4.5. Quantitation of JP-Gly-OH relative to (A) JP-NH2 and (B) JP-Gly in the pituitaries of 
WT and PAM
+/-
mice on a normal diet. JP-Gly-OH/JP-NH2 in WT mice was compared to the 
same ratio in PAM
+/- 
mice. JP-Gly-OH/JP-Gly was compared to 1 in WT and PAM
+/- 
mice, 
respectively. N is the number of biological replicates. Error bar, SEM. Student’s t-test: **, 
p<0.05; *, p<0.1. 
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5.2 Introduction 
Neurons and glia are the two main types of cells in the central nervous system (CNS). 
Neurons are well known to play an important role in the functions of the CNS.
1
 Glia, although 
present in higher numbers than neurons,
2
 have long been considered passive companies to 
neurons. The active roles of glia in the CNS have only been discovered within the past three 
decades. Astrocytes, a predominant subtype of glia, have gained considerable interest recently.
3
 
They are involved in the brain circuitry by integrating neuronal signals, exhibiting Ca
2+
 
excitability, and processing information.
4
 These studies initiated the concept of tripartite synapse, 
which indicates the communication between the pre- and post-synaptic terminal of neurons and 
the surrounding astrocytes.
5,6
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Astrocytes are located close to synapses of neurons and blood capillaries, facilitating the 
regulation of both synaptic transmission and neurovascular coupling.
4,7
 Glial fibrillary acidic 
protein (GFAP) is a well characterized marker for astrocytes, and its immunostaining results 
shows astrocytes, as named, are star-shaped. However, more recent morphological analysis of 
astrocytes in the hippocampus shows that astrocytes are more spongiform-shaped, and occupy 
restricted and independent spatial territories.
8-10
 This structure undergoes remodelling in 
situations from acute injury to neurodegenerative diseases.
11
 For example, the processes of 
nearby astrocytes interdigitate after multiple epileptic seizures. Astrocytes interconnect through 
gap junction channels consisting of connexins (Cxs) in the network.
12
 Cx channels have recently 
been shown as selective channels for second messengers (e.g. cyclic AMP and Ca
2+
), amino 
acids, nucleotides, and energy metabolites (e.g. glucose), small peptides (e.g. glutathione) and 
RNA (24mer).
13,14
 The expression of Cxs is also closely related brain dysfunction.
12
    
Not only the astrocyte network but also the glial-neuronal network plays an important 
role in the CNS. From a molecular perspective, astrocytes express membrane ion channels,
15,16
 
neurotransmitters,
4
 and receptors
17
 related to important signaling pathways in the CNS, which 
provide foundation for glial-neuronal communication. Recent studies have shown that astrocytes 
may modulate synaptic transmission by releasing small signaling molecules such as glutamate,
18
 
ATP,
19
 and D-serine
20
 in response to various stimuli that evoke Ca
2+
 increase.
21
 Although 
gliotransmission is still a controversial topic, these studies support the idea that astrocytes 
participate in information processing.
22
 In addition, gliotransmitters were defined as those 
molecules: (1) synthesized by and/or stored in glia; (2) released in a regulated pathway triggered 
by physiological and/or pathological stimuli; (3) activating rapidly (milliseconds to seconds) 
responses in neighboring cells; and (4) playing a role in physiological processes.
23
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Compared to small molecules, bioactive peptides, which are involved in high-level 
functions in the CNS, are less well characterized in astrocytes. Neuropeptide precursors are made 
in the endoplasmic reticulum, transit Golgi compartments, and are processed into neuropeptides 
in the dense-core vesicles before release. Secretogranin II, a protein involved in the packaging or 
sorting of peptide hormones and neuropeptides into the dense-core vesicles, has been studied in 
astrocytes.
24
 Interestingly, secretogranin II was seen in some smaller and less dense vesicles as 
well as the typical dense-core vesicles, indicating different morphological appearance of 
peptidergic granules in astrocytes.
24
 Atrial natriuretic peptide (ANP) is another peptide studied in 
astrocyte exocytotic release. However, this study relied on an introduction of constructed peptide 
precursor.
25
 Neuropeptide Y (NPY) has also been reported in and released from cortical 
astrocytes.
26
 We would like to characterize more astrocyte peptides. Analogous to the term 
neuropeptidome to describe the complement of peptides used by a neuronal network, knowledge 
of the astrocyte peptidome would greatly aid our understanding of the interactions between 
astrocytes and neurons. As described above, the astrocyte network is closely related with brain 
dysfunctions. Studies on the bioactive molecules in astrocytes may uncover molecular hallmarks 
for such neurological diseases as Alzheimer’s disease27 and amyotrophic lateral sclerosis.28 
Most studies on the astrocyte peptidome have used mRNA detection or immunoassays. 
Shinoda et al. reported the presence of several prohormone transcripts in cultured astrocytes,
29
 
and subsequent studies demonstrated the immunoreactivity of some neuropeptides such as Met-
enkaphalin
30
 in astrocytes. However, observing prohormone mRNA is not equivalent to the 
presence of biologically active peptides. A prohormone is not bioactive until it is processed into 
the appropriate peptides. Because of unconventional prohormone processing and a large number 
of post-translational modifications (even those that may be glia specific), it can be difficult to 
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predict the bioactive peptides arising from a poorly-characterized prohormone. Immunoreactivity 
detection is also limited by the accessibility and specificity of antibodies for detecting bioactive 
peptides.
31
  
As highlighted in prior chapters, mass spectrometry (MS) has been successfully applied 
to characterize biological molecules due to its high sensitivity and its capability to identify 
peptides using sequence information.
32
 The hyphenation of liquid chromatography (LC) to MS 
provides additional advantages for investigating complex biological samples by reducing ion 
suppression. In this work, capillary liquid chromatography coupled off-line with matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (LC-MALDI-TOF MS) is used for 
peptide profiling of astrocytes, and the identification of detectable putative peptides is 
accomplished by both MALDI-TOF tandem MS and electrospray ionization ion-trap tandem 
mass spectrometry (ESI-IT MS/MS). In addition, we performed regulated secretion studies on 
the astrocyte cell cultures by comparing the peptide profiles of the cell media before and after the 
Ca
2+
-evoked stimulations. Different stimuli were investigated, and peptides of interest were 
found in astrocytes since the fraction of the astrocyte peptidome released in a physiologically 
dependent manner is more likely to be important cell-cell signaling molecules. 
5.3 Experimental 
5.3.1 Cells 
Astrocyte type I cell line (C8-D1A) derived from the cerebellum of C57BL/6 mice was 
purchased from American Type Cell Collection (ATCC).
33
 The cell culture media was prepared 
following the instruction in ATCC. Primary cultured astrocytes from rat hippocampal and 
cortical tissues were obtained from the Gillette lab. The cell line does not have strong GFAP (a 
133 
 
maker for some types of astrocytes) signals, and the primary cultures have 95%-98% cells 
recognized by GFAP. No neurons are present based on staining results from all the samples.  
5.3.2 Peptides in Astrocytes 
For peptidomics study, two sample preparation protocols were performed. Initially, 
astrocyte cell line or rat hippocampal primary cultures were rinsed with serum-free medium, 
boiled in water for 5 min, and extracted with iced 0.25% acetic acid prior to being pooled for cell 
pellets by scraping.
34
 The homogenates were centrifuged down, and the supernatant was pre-
concentrated with C18 spin columns (Pierce, Rockford, IL) before further analysis. At the same 
time, we applied a previously published protocol to study the peptidomics of cultured astrocytes 
from rat cortical tissue.
26
 Specifically, the cell cultures were washed with HBSS, extracted with 
1–2 mL of 10 mM HCl, and then collected by scraping. TFA (0.1% as a final concentration) was 
added and the samples were sonicated for 2–3 min before the incubation at 70°C for 20 min. The 
cell extracts were then centrifuged at 6000 rpm for 10 min, and the supernatant was applied to a 
10 kDa cutoff Centricon filter (Nanosep 10K Omega, Pall Corporation). The flow-through was 
lyophilized, and the sample extracts was re-suspended in 20 µL of 0.1% TFA aqueous solution. 
The samples were further desalted with ZipTipC18 (Millipore) before MS-based analysis. The 
cell culture medium was prepared in the same way as a control. 
LC-MALDI-TOF MS was used for peptide profiling of astrocyte cell line and primary 
cell cultures from rat hippocampus, and subsequently tandem MS was performed to sequence 
peptides of interest. The samples were separated by a CapLC system (Micromass, Manchester, 
UK) with a capillary column (LC Packings™ 300 μm i.d. × 15 cm, C18 PepMap100, 3 μm 
particle size, 100 Å pores, San Francisco, CA) at a flow rate of 2 L/min in a gradient from 2% 
to 10% B in the first 7 min, continuing to 20% in 3 min, ramping up to 40% B in another 15 min, 
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reaching 80% B in 7 min, maintaining at 80% B for 3 min before going down back to 2%. A 
total of 24 one-minute fractions were collected between 20-45 min during the separation. The 
fractions were then mixed with 10 mg/mL -cyano-4-hydroxycinnamic acid (-CHCA) for 
Ultraflex II MALDI-TOF/TOF MS and MS/MS studies (Bruker Daltonics, Bremen, Germany) in 
the mass range of 800-5000 Da. FlexAnalysis (Bruker Daltonics, Bremen, Germany) was used 
for data analysis, and the observed masses were matched to the peptides derived or predicted 
from reported neuropeptide precursors in glial cells. NeuroPred (http://neuroproteomics.scs. 
illinois.edu/neuropred.html) was utilized to create the predicted peptide mass list.
35
 
LC-ESI-IT MS/MS was applied for better peptide sequencing. More concentrated 
samples were loaded on the same CapLC system, and separated with a longer gradient which 
started at 2% B, slowly went to 5% in 8 min, continued to 20% B in another 7 min, up to 40% B 
in 40 min, ramped to 65% B in 20 min, reached 80% B in 3 min, and stayed at 80% B for 4 min 
before coming down to 2% B. The HCTultra ESI-IT MS (Bruker Daltonics, Bremen, Germany) 
was operated through EsquireControl in the mass range of 400-2400 m/z with target mass of 800 
m/z. A data-dependent tandem MS was activated once the parent ion reach a certain threshold 
(e.g. 10
5
). The peptide extracts from rat cortical tissue prepared using the second protocol were 
only subjected to LC-ESI-IT MS/MS. DataAnalysis software (Bruker Daltonics, Bremen, 
Germany) was used to display MS and MS/MS spectra, and create a compound list with MS/MS 
after deconvolution. Both Mascot (www.matrixscience.com, Matrix Science, London, UK) and 
Peaks Studios (Bioinformatics Solutions Inc., Waterloo, ON, Canada) were used for database 
searching and automatic de novo sequencing. The sequence tags generated through de novo 
sequencing were searched against the protein database with protein blast or against translated 
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nucleotide database with tblastn in Basic Local Alignment Search Tool (BLAST) at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi.    
5.3.3  Peptides Released from Astrocytes 
To better understand the functions of signaling molecules, the astrocyte cell line from 
mouse cerebellum and primary cultured cells from rat hippocampus were stimulated with various 
chemicals that were reported to trigger Ca
2+ 
waves in astrocytes, and thus induced the regulated 
release. These chemicals include 5 M ionomycin, 55 mM KCl, 100 M or 1 mM glutamate, 
brandykinin in different concentrations (100 nM, 1 M, 100 , and 1 mM), and 1 M 
serotonin. The cells were cultured in the serum-containing medium, and were either stimulated in 
the serum-containing medium or serum-free medium for a certain time dependent on different 
stimuli. The pre- and post-stimulated media were collected as the control and experimental 
samples, and centrifuged at 11000 rpm for 10 min. The supernatants were desalted and pre-
concentrated with C18 cartridge (Waters, Milford, MA). The solvent of the eluent was 
evaporated with Savant SpeedVac Vacuum Concentrator (Thermo Scientific, Waltham, MA). 
The peptides were re-constituted into 0.1% FA and 0.01% TFA aqueous solution. 
The control and experimental samples were sequentially subject to LC-MALDI-TOF MS 
analysis as described above. The gradient started at 3% B, run to 5% B in 5 min, continued to 
30% B in 18 min, ramp up to 80% B in 3 min, stayed at 80% B for 2 min before ramping back to 
and maintain at 3% B. A total of 24 one-minute fractions were collected between 16 min and 45 
min. -cyano-4-hydroxycinnamic acid (-CHCA, 10 mg/mL) was used as matrix for the further 
measurement with Ultraflex II MALDI-TOF/TOF MS (Bruker Daltonics, Bremen, Germany).  
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5.4 Results and Discussions 
5.4.1 Peptide Profiling of Astrocytes 
A number of compounds in the peptide mass range have been detected in astrocyte 
extracts with MALDI-TOF MS (Figure 5.1). The results from the cell extracts were compared 
with the corresponding control from cell culture medium to reduce the interference from the 
serum peptides. Thymosin-4, known to be widely distributed in mammalian brains, was 
observed and identified in the cell extracts. In the mass range of 800-5000 Da, a total of 167 
peaks (after subtracting controls) were detected from astrocyte cell lines, among which 19 peaks 
can be mass-matched to known neuropeptides (Table 5.1) In the same mass range, a total of 249 
peaks were observed in the primary cultured astrocytes, among which 23 were putatively 
identified as known neuropeptides by mass-matching (Table 5.1).  
5.4.2 Peptide Sequencing 
A higher confidence in peptide identification relies on obtaining tandem MS information 
from the mass-matched peptides. However, the amounts of these peptides are too low to produce 
fragment ions with good coverage information by using MALDI-TOF tandem MS. Although a 
number of observed peaks produced tandem MS in MALDI-TOF MS, none of them can be 
directly used for peptide identification with incomplete sequence information (Figure 5.2). 
However, these data may become useful as a database to assist in analyzing the molecules with 
putative sequences in future (Table 5.2).   
Compared with MALDI-TOF tandem MS, ESI-IT MS/MS is often able to provide less 
complicated spectra with more complete sequence coverage.
36
 Hence, the peptide identification 
were mainly accomplished with LC-ESI-IT MS/MS. LC-ESI-IT MS is not as sensitive as LC-
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MALDI-TOF MS, and it often provides a complementary set of peptides from those detected in 
LC-MALDI-TOF MS. In such cases, we were unable to have ESI-IT MS/MS data for the 
confirmation of the peptides whose masses matched to known or predicted peptides observed in 
LC-MALDI-TOF MS. Instead, we were able to identify some peptides derived from proteins 
with Mascot (Table 5.4) or putatively from some precursors with Peaks Studio (Table 5.5).  
For control purpose, we analyzed the culture medium to create a serum peptide database 
(Table 5.3). Although serum-free medium was used to reduce the interference of serum peaks in 
the cell extracts, the serum peaks were not entirely eliminated, and some of these peaks still 
dominate in the MS/MS spectra. Because these peaks derived from the medium incubated 
without the cell presence, and underwent the same sample procedure as cell extracts, the 
abundant identified serum peaks indicate a big obstacle for the detection of peptides in much 
lower levels. These identified peaks could be put in the exclusion mass list for MS/MS to 
diminish the ion suppression, or be skipped during de novo sequencing, thus improving data 
analysis efficiency.  
A number of peptides derived from proteins were identified with ESI-IT MS/MS and 
database searches using Mascot (Table 5.4). Although some peptides appear to arise during the 
extraction procedure (e.g. Asp-Pro cleavage induced by hot acid), not all of them are likely to be 
the protein degradation products since different extraction protocols were used; protease activity 
was reduced in these protocols;
37
 and protein degradation products are generally very 
unstable.
38,39
 These identified peptides have some interesting features. Firstly, most of these 
identified peptides are derived from either N- or C-terminal of the proteins, suggesting selective 
cleavages may contribute to the peptide production. Secondly, these peptides are stable enough 
to be detected. N-terminal acetylation in some peptides would probably protect them from 
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aminopeptidases. Thirdly, the most common amino acid residue is Ala, and the cleavages 
frequently occurred at hydrophobic sites such as Leu. The calpains, a class of calcium-activated 
cytosolic enzymes, is known to perform the cleavages of proteins often at hydrophobic site.
40
 
Non-classical neuropeptides derived from non-secretory pathway proteins have been recently 
proposed by Lloyd Fricker.
41
 The peptides identified in astrocyte extracts meet the criteria of 
non-classical neuropeptides. It is not surprizing to identify about half non-secretory pathway 
peptides in a typical peptidomics work on tissue since tissue includes high volume of glia as well 
as neurons. Further studies are needed to determine the pathways in the generation of these so 
called non-classical neuropeptides. 
Classical neuropeptides derived from precursors such as proenkephalin and 
proopiomelanocortin have been shown to have multiple biological functions. Are the non-
classical neuropeptides functional? Some related studies have been done with diazepine binding 
inhibitor,
42
 hemorphins,
43,44
 and hippocampal cholinergic stimulating neuropeptide (HCNP).
45-50
 
HCNP was identified in the astrocytes in our work. It is the N-terminal fragment of 
phosphatidylethanolamine-binding protein (PEBP) with acetylation, and has been shown to act 
as a endocrine factor in cardiac physiology,
45
 involve hippocampal cholinergic circuitry,
46
 evoke 
a depressive-like phenotype,
47
 and even potentially associate with learning and memory.
49
 In 
addition, the expression level of HCNP precursor was thought to be a key regulator to 
differentiate cultured adult rat hippocampal progenitor cells into specific neural lineages.
50
 
Interestingly, a peptide with one more amino acid at C-terminal of HCNP was also identified in 
the same sample, and a C-terminal fragment of PEBP (HCNP precursor protein) was identified 
in the astrocyte cell line extracts from mouse cerebellum using Peaks Studio. 
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Some molecules were well fragmented in ESI-IT MS/MS, however, they did not match to 
any peptides with database searching. Manual de novo sequencing of these peptides was 
performed to produce partial sequence tags, and auto de novo sequencing from both Mascot and 
Peaks Studio was used to confirm and elongate the sequence tags (Table 5.6). De novo 
sequencing is challenging as shown in Chapter 1, and plays an important role in charactering 
post-translational modifications.
41
 Although the sequence tags observed in our work are too short 
to be used in searching with BLAST, they can serve as a partial sequence database for the 
confirmation of peptide identification with putative sequence in the future work.  
5.4.3 Peptide Released from Astrocytes 
While identification of astrocyte peptides provided a database for potential signaling 
molecules, the study on peptides released from astrocytes upon stimulation is of more scientific 
interest because the astrocyte peptides released in a physiologically dependent manner are more 
likely to be important cell-cell signaling molecules. Different chemical stimuli were applied to 
the astrocyte cell cultures. While the mechanisms of these stimuli to induce the astrocyte release 
are not entirely clear, all stimuli were reported to trigger the Ca
2+
 increase in astrocytes. The 
observed different responses of the same types of astrocytes to the chemical stimuli indicate that 
the profile of peptides released from astrocytes may depend on different stimulation mechanisms. 
Ionomycin is an ionophore which allows extracellular Ca
2+
 to enter the cells.
51,52
 The 
stimulation of astrocyte cell lines with 5 M ionomycin for 15 min produced 64 peaks 
(subtracting the control) in the peptide mass range. This stimulation caused detachment of some 
cells from the culture flask. Elevated levels of extracellular K
+
 depolarizes astrocytes and 
increases the permeability of gap junctions.
53
 Similar to ionomycin, the addition of KCl also 
detached cells from the cell flask. However, among the observed 67 peaks (subtracting the 
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control) in KCl post-stimulation medium, only 3 peaks were the same as those in ionomycin 
post-stimulation medium.  
Glutamate, a small molecule secretagogue, was reported to induce the astrocyte 
secretion.
26,54,55
 However, we didn’t observe any difference in the peptide mass range between 
the control and experimental samples stimulated with 100 M or 1 mM glutatmate, indicating 
different types of astrocytes may have different responses to the same stimulus. Serotonin, 
another important neurotransmitter in the mammalian central nervous system (CNS),
56
 is taken 
by astrocytes
57
 and thus increases their intracellular Ca
2+
 concentration.
58-60
 Different from 
glutamate, 1 M serotonin caused 28 peaks (subtracting the control) to be observed in the post-
stimulation medium, with two peaks shared by ionomycin and KCl stimulations, respectively.     
Bradykinin is a more selective stimulus since it induces the increase of internal Ca
2+
 in 
astrocytes but not in neurons.
61
 In this work, the astrocyte cell line cultures were exposed to 
different concentrations of bradykinin for 30 min. No difference in the peptide mass range was 
observed in the post-stimulated medium with 100 nM bradykinin compared to the control sample, 
which is consistent with the previous study.
26
 1 M BK was selected for further analysis instead 
of 100 M or 1mM because this concentration is high enough to induce astrocyte secretion, 
while remaining low enough not to interfere with MS detection. The primary astrocyte cells from 
rat hippocampus were subject to 1 M BK and 1 M serotonin, respectively, producing 45 peaks 
in response to BK and 28 peaks in response to serotonin with 6 sharing peaks.  
Then we matched the identified peptides in astrocytes with the molecules released from 
astrocytes in response to various chemical stimuli. As shown in Table 5.7, most of these peptides 
are C-terminal fragments of the cytosolic proteins or cleaved at Leu. More physiological tests are 
needed to investigate the functions of these non-classically processed peptides. At the same time, 
141 
 
the released peptides not observed in astrocytes may be also of scientific interest because 
reactive astrocytes have been shown to act differently from regular astrocytes. Reactive 
astrocytes are reported to produce various neurotrophic factors and cytokines, therefore they are 
more likely to be a key of a dynamic environment to interact with neurons.
62
 Studies have shown 
that reactive astrocytes provide essential activities to restrict inflammation and protect 
neurons.
63,64
 Therefore, better understanding the reactive astrocytes may lead to novel 
approaches to limit tissue degeneration and preserve functions after nervous system injury. 
Therefore, effort was made to identify the peptides in the post-stimulation medium with tandem 
MS following the LC-MALDI-TOF MS detection (Table 5.8). 
5.5 Conclusions and Future Directions  
Although we have not identified classical neuropeptides with good tandem MS, we 
identified a set of peptides derived from cytosolic proteins in either astrocyte cell line from 
mouse cerebellum or primary astrocyte cultures from rat hippocampus or mouse cortical tissue. 
Although many studies have shown that peptides derived from intracellular proteins have 
biological functions, more studies are needed to establish these are physiologically relevant. 
Some studies could be conducted to investigate the functions of the identified molecules, 
especially those observed in the astrocyte secretion study. Although hippocampal cholinergic 
stimulating neuropeptide was identified in the cell extracts but not in the astrocyte secretion 
study, it is still of scientific interest since a number of studies have shown some of its 
functions.
45-47,49,50
  
From a peptidomics point of view, several factors should be considered to select the 
samples to examine the presence of classical neuropeptides in glia. Previous studies showed that 
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hippocampus in animals at an early development stage may be a good candidate. Astrocytes, as 
one main cell population in glia, themselves comprise a heterogeneous population, and have not 
been well defined. The differences of astrocytes depending on brain region and developmental 
stage have been shown in many studies on gap junction coupling, exocytosis associated protein 
expression, putative neuropeptides, transmitter receptor expression, membrane currents, and 
glutamate transporters.
65
 For example, the number and size of Cx43 and Cx30, two main gap 
junction proteins in astrocytes,
66-69
 as well as the level of astrocyte coupling, decline in the aging 
brain.
70,71
 Astrocyte coupling increases in the hippocampus and the cortex during the first 
postnatal weeks.
72-75
 Somatostatin mRNA and peptides decrease from embryo rats to rat adult.
76
 
At the same time, hypothalamic and hippocampal glia express significantly more proenkephalin 
mRNA than striatal, cortical, or cerebellar glia.
77
 Secretogranin II, a dense-core vesicle marker, 
was immunodetected in hippocampal astrocytes, but not in cerebellar astrocytes.
24
  
Cell cultures are good models to study a large population of homogeneous cells and cell 
secretion, however, they’re actually located in a very different environment from the cells in 
tissue which are surrounded by different types of cells including neurons. Expression of 
exocytosis associated proteins in rat cerebral cortices was reported to decrease from 2 day 
cultures to 20 day cultures.
24
 Can we work with glial cells directly isolated from the brain? The 
availability of transgenic mice
78
 with visualized astrocytes by green fluorescent protein and the 
development of cell sorting
79,80
 are providing us the  opportunities to work on the glial cells 
directly from tissue. As far as enough cells are collected, a traditional peptidomics procedure as 
described above will be applied to examine the peptide content of these cells. 
An alternative method to collect concentrated peptides in glia is directly sampling from 
peptide-containing vesicles. Neurons store neuropeptides in the dense-core vesicles, and 
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astrocytes are reported to possess similar vesicles in different morphologies.
24,81
 The isolation of 
clear-core vesicles with magnetic beads has been successfully applied to study the D-serine in 
astrocytes (data to be published). The capability of isolating peptide-containing vesicles in 
astrocytes will be of great help in astrocyte secretory peptides and its pathway studies.  
The secretion study of astrocytes is of great scientific interest. It is reported that abnormal 
astrocytes may secrete substances that kill motor neurons in ALS.
82
 There was a greater loss of 
normal neurons in the presence of superoxide dismutase (SOD1) mutant astrocytes than SOD1 
mutant neurons in the presence of normal astrocytes, which may indicate that normal astrocytes 
protect neurons while deficit astrocytes could cause some diseases. In such cases, the studies 
may be also directed towards the astrocytes in diseased models, which may uncover potential 
targets for drug development.
5,83
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5.6 Figures 
 
 
 
Figure 5.1. Peptide profile of astrocyte cell line analyzed by LC-MALDI-TOF MS. 
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Figure 5.2. Examples of LC-MALDI-TOF tandem mass spectra from glial cell extracts.
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Table 5.2. Peptides in astrocytes analyzed with LC-MALDI-TOF tandem MS and the data paths. 
MH
+
obs. Acquisition Date: mmddyy_(Sample Spot) Astrocyte Cell line Primary Cultures 
886.98 101907_(M&N) X - 
904.49 091007_(H) - X 
905.69 091007_(H), 091207_(H) - X 
915.81 091207_(H) - X 
918.98 091907_(K) - X 
923.75 101907 (G) X - 
926.39 020908_(H) X - 
927.66 091007_(H) - X 
952.58 101907_(O) X - 
1003.65 091007_(H) - X 
1008.33 091007_(H) - X 
1010.54 091007_(H) - X 
1014.20 051507 (H) - - 
1015.54 020908_(H) X - 
1018.61 020908_(H) X - 
1034.60 020908_(H) X - 
1055.66 101907_(O) X - 
1079.65 020908_(H) X - 
1086.61 091907_(K) - X 
1097.54 101907_(G) X - 
1107.96 091007_(H) - X 
1117.62 080207_(D), 020908_(H), 091207_(H), 
091007_(H), 091907_(K) 
X X 
1141.56 091007_(H), 91207_(H) - X 
1145.87 061407 (I) - - 
1173.57 091007_(H) - X 
1174.83 061407_(I) X - 
1189.66 020908_(H) X - 
1216.73 020908_(H) X - 
1218.59 101907_(G) X - 
1228.74 101907_(G) X - 
1253.65 051507_(H) X - 
1255.71 101907_(O) X - 
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Table 5.2 (cont.) 
MH
+
obs. Acquisition Date: mmddyy_(Sample Spot) Astrocyte Cell line Primary Cultures 
1259.72 091007_(H), 091207_(H), 091907_(K) - X 
1261.59 091007_(H) - X 
1267.70 020908_(H) X - 
1303.73 080207_(D) X - 
1317.65 101907_(O) X - 
1321.77 051507_(H) X - 
1325.47 020908_(H) X - 
1331.68 091907_(K) - X 
1337.69 091007_(H) - X 
1401.01 061407_(I) X - 
1456.73 080207_(D) X - 
1466.80 091007_(H), 101907_(O) X X 
1519.85 101907_(G) X - 
1539.82 020908_(H) X - 
1547.81 091007_(H) - X 
1581.75 101907_(O) X - 
1594.80 020908_(H) X - 
1600.80 101907_(G) X - 
1647.71 080207_(D), 101907_(M&N), 020908_(H) X - 
1681.83 020908_(H) X - 
1850.92 091007_(H), 101907_(O) X X 
1918.03 080207_(D) X - 
1969.40 061407_(I) X - 
2030.99 091007_(H), 091207_(H),101907_(O) X X 
2174.18 020908_(H), 60707_(C) X - 
2174.67 061407_(I) X - 
2353.19 091007_(H) - X 
2371.45 061407_(I) X - 
2372.46 061407_(I) X - 
2647.44 60707_(C) X - 
3556.75 60707_(C) X - 
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Table 5.3. Identified serum peptides in the culture medium with LC-ESI-IT MS/MS and Mascot. 
Bovine Protein Peptide Sequence m/z z 
Fibrinogen alpha E.DGSDPPSGDFLTEGGGV.R 803.9 2 
 -.EDGSDPPSGDFLTEGGGV.R 868.4 2 
 D.PPSGDFLTEGGGV.R 616.9 2 
 R.GDSVSQGTGLAPGSPR.K 743.5 2 
 R.TGLAPEFAALGESGSSSSK.T 898.5 2 
 M.EDEAESLEDLGF.K 677.4 2 
 K.MEDEAESLEDLGF.K 742.9 2 
 K.oxMEDEAESLEDLGF.K 750.4 2 
 R.TGLAPEFAALGESGSSSS.K 834.4 2 
 -. pyro-QFPTDYDEGQDDRPKVG.L 975.6 2 
Alpha-1-antitrypsin L.YDRNTKSPLFVGKVVNPTQA.- 1117.8 2 
Apolipoprotein A-I R.pyro-QGLLPVLE.S 851.6 1 
 K.VSILAAIDEASK.K 608.4 2 
 R.EQLGPVTQEFWDNLEK.E 967.0 2 
 R.EQLGPVTQEFWDNLM.K 903.5 2 
 K.VREQLGPVTQEFWDNLEK.E 730.1 3 
 L.AAIDEASKKLNAQ.- 680.1 2 
Apolipoprotein A-II A.GTDLLNFLSSFIDPKKQP.A 674.1 3 
 A.GTDLLNFLSSFIDPKKQPAT.- 1096.7 2 
 A.GTDLLNFLSSFIDPKKQPAT.- 731.5 3 
 K.KAGTDLLNFLSSFIDPKKQPAT.- 797.8 3 
 K.KAGTDLLNFLSSFIDPKKQPAT.- 1196.6 2 
 T.pyro-QEELTPFF.K 993.5 1 
 K.TQEELTPFFK.K 620.4 2 
 -.pyro-QAEESNLQSLVSQY.F 789.9 2 
 -.pyro-QAEESNLQSLVSQYF.Q 863.4 2 
Albumin R.KVPQVSTPTLVEVSR.S 820.6 2 
 R.KVPQVSTPTLVEVSR.S 547.4 2 
 R.KVPQVSTPTLVEV.S 699.0 2 
 K.DAIPENLPPLTADF.A 756.4 2 
 R.ALKAWSVAR.L 501.4 2 
 R.DTHKSEIAHR.F 597.5 2 
 R.KVPQVSTPTLVEVSRSLGK.V 675.9 2 
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Table 5.3 (cont.) 
Bovine Protein Peptide Sequence m/z z 
Albumin R.DTHKSEIAHRFKD.L 792.6 2 
 R.DTHKSEIAHRFKDLG.E 877.6 2 
Hemoglobin beta K.VDEVGGEALGR.L 551.4 2 
 K.VKVDEVGGEAL.G 558.4 2 
 K.VVTGVANALAHR.Y 604.4 2 
 K.VKVDEVGGEALGR.L 665.0 2 
 R.FGSEFSPELQASFQK.V 851.5 2 
 F.ESFGDLSSADAILGNPK.V 861.0 2 
 F.FESFGDLSSADAILGNPK.V 934.5 2 
 R.FFESFGDLSSADAILGNPK.V 1008.0 2 
 V.KVDEVGGEALGR.L 615.5 2 
 E.SFGDLSSADAILGNPK.V 796.5 2 
 F.FESFGDLSSADAILGNPK.V 623.5 3 
 R.FFESFGDLSSADAILGNPK.V 672.4 3 
Hemoglobin alpha K.AVEHLDDLPGALSELSDL.H 947.5 2 
 K.AVEHLDDLPGALSELSDLHAH.K 747.1 3 
 K.AVEHLDDLPGALSELSDLHAH.K 1120.0 2 
 K.AVEHLDDLPGALSELSDLHAHK.L 789.8 3 
 L.VTLASHLPSDFTPAVH.A 846.4 2 
 K.VGGHAAEYGAEALER.M 765.4 2 
Fetuin S.GVASVESSSGEAF.H 613.9 2 
 F.SGVASVESSSGEAF.H 657.4 2 
 H.TFSGVASVESSSGEAF.H 781.4 2 
 R.HTFSGVASVESSSGEAF.H 849.9 2 
 F.SGVASVESSSGEAFHVGK.T 868.0 2 
 R.HTFSGVASVESSSGEAFHVGK.T 707.4 3 
 A.pyro-QFVPLPVSVSV.E 1154.7 1 
 F.SGVASVESSSGEAFHVGK.T 579.0 3 
 R.HTFSGVASVESSSGEAFHVGK.T 1060.6 2 
 K.HTLNQIDSVK.V 577.9 2 
 S.IPLDPVAGYK.E 1072.8 1 
 S.IPLDPVAGYK.E 536.8 2 
 Y.actyl-KEPACDDPDTEQAALAAVDYINKHLPR.G 1007.9 3 
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Table 5.4. Glial peptides identified with LC-ESI-IT MS/MS and Mascot. 
Protein Peptide Sequence m/z z 
Actin beta D.ESGPSIVHRKCF.- 679.5 2 
 K.IIAPPERKYS.V 587.7 2 
 L.RVAPEEHPVL.L 574.3 2 
 L.YASGRTTGIVM.D 578.8 2 
 W.IGGSILASLSTFQQ.M 712.1 2 
 M.WISKQEYDESGPSIVHRKCF.- 804.6 3 
 W.ISKQEYDESGPSIVHRK.C 987.5 2 
 W.ISKQEYDESGPSIVHRKCF.- 1112.2 2 
 W.ISKQEYDESGPSIVHRK.C 657.8 3 
 Y.NELRVAPEEHPVL.L 752.3 2 
Actinin alpha L.YGESDL.- 683.8 1 
Acyl-CoA-binding protein M.acetyl-SQADFDKAAEEVKRLK.T 626.5 3 
Calcium binding protein L.ALIYNEALK.- 518.3 2 
 F.LQTSQKRI.- 487.8 2 
 L.IGGLAIACHESF.L 609.9 2 
 M.PTETERCIESL.I 639.7 2 
 L.IYNEALK.- 426.1 2 
Calmodulin 1 M.ADQLTEEQIAE.F 644.9 2 
Calmodulin 2 E.FVQMMTAK.- 478.9 2 
Cd2 molecule T.DVELKL.Y 715.8 1 
Elongation factor 1-beta  M. GFGDLKTPAGLQVLNDYL. A 961.5 2 
Enolase L.YTAKGLFR.A 955.8 1 
Eukaryotic translation 
Elongation factor 1 beta 2 
E.AAVAIKAMAK.- 661.9 2 
Galectin-1 E.VASDAKSFVLNL.G 632.6 2 
 V.RGEVASDAKSFVLNL.G 803.9 2 
Glutamine synthetase 1 L.LNETGDEPFQYKN.- 778.5 2 
Glyceraldehyde-3-hosphate 
dehydrogenase 
L.MAYMASKE.- 466.4 2 
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Table 5.4 (cont.) 
Proteins Peptide Sequence m/z z 
Glyceraldehyde-3-hosphate 
dehydrogenase 
G.YSNRVVDL.M 483.7 2 
 D.PANIKWGDAGAEY.V 697.5 2 
 L.ISWYDNEYGYSNRVVDL.M 1047.8 2 
 L.MAYMASKE.- 929.7 1 
lgE-dependent histamine-
releasing factor 
L.LEGKVLPGVDALSNV.- 755.1 2 
Macrophage migration 
inhibitory factor 
-.PMFIVNTNVPRASVPEGFLSEL.T 806.7 3 
 L.AQATGKPAQYIAVHVVPDQLMTF.S 829.2 3 
 L.AQATGKPAQYIAVHVVPDQL.M 1054.4 2 
 V.PRASVPEGFLSELTQQL.A 937.2 2 
Myosin regulatory light 
chain RLC-A 
E.FTRILKHGAKDKDD. 822.6 2 
Phosphatidylethanolamine-
binding protein 
M.acetyl-AADISQWAGPL.S 586.3 2 
 M. acetyl-AADISQWAGPLS.L 629.8 2 
Peptidylprolyl isomerase A F.DITADGEPLGR.V 1143.9 1 
 M.VNPTVFFDITADDEPLGRVSF.E 1170.6 2 
 F.EDENFILKHTGPGILSM.A 951.8 2 
 F.DITADGEPLGR.V 572.7 2 
 F.FDITADGEPLGR.V 646.2 2 
 F.FDITADGEPLGRVC.F 747.5 2 
Phosphoglycerate kinase 1 L.LEGKVLPGVDALSNV.- 756.5 2 
Peroxiredoxin-5 C.SLAPNILSQL.- 528.4 2 
Protein S100 F.LQTSQKRI.- 973.8 1 
Heat shock 27 protein E.ARAQIGGPESEQSGAK.- 793.7 2 
 M. acetyl-TERRVPFSLLR.S 473.1 3 
Sec31l1 protein L.KVVLSQASKLGV.- 614.9 2 
Thymosin beta-4 precursor -. acetyl-SDKPDMAEIEKFDKSKLK.K 718.4 3 
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Table 5.4 (cont.) 
Proteins Peptide Sequence m/z z 
Thymosin beta-4 precursor M. acetyl-SDKPDMAEIEKFD.K 784.1 2 
Thyroid hormone receptor-
binding protein 
R.oxMPoxMPVNTPLGSNSRKoxMVY.Q 1035.1 3 
Transgelin (Smooth muscle 
protein 22-alpha) 
R.GASQAGMTGYGRP.R 627.3 2 
 L.FEGKDMAAVQRTVMALGSL.A 1013.0 2 
Translocating chain-
associating membrane 
protein 
G. acetyl-RSSRKGTENGV.N 617.7 2 
Tubulin polyglutamylase 
TTLL5 
R.PLSASDAE(Ox)MKNLVASAR.E 889.1 2 
Tyrosinase acetyl-SWLLGAAMVGAVLTALLAGL 985.7 2 
Vimentin D.GQVINETSQHHDDLE.- 862.2 2 
 K.TVETRDGQVINETSQHHDD.L 1091.7 2 
 -. acetyl-STRSVSSSSYRRMFG.G 584.3 3 
 K.TVETRDGQVINETSQHHDD.L 727.8 3 
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Table 5.5. Putatively identified peptides in astrocyte cell lines with LC-ESI-IT MS/MS and 
Peaks Studio. 
 Precursor/Protein Sequence m/z z 
SMS L. Pyro-QKSLAAATGKQELA. K  700 2 
beta-NGF E.TKCRASNPVESGC.R 676.9 2 
BDNF P.PLLF.L 489.3 1 
NRTN R.IPGP.RRR 383.4 1 
 A.RLAQYRALLQGAP.D 729 2 
VIP D.FLEELE.K 779.5 1 
PSARL R.YG.PSLGASGAIMTV.L 552.4 2 
PEBP Y.QAEWDDYVPKLYEQLSGK.- 1076.5 2 
ANP R.IDRIGAQSGLG.C 543.9 2 
MIF M.PMFIVNTNV.P 1033.2 1 
 
Abbreviations: SMS, somatostatin; NGF, nerve growth factor; BDNF, brain-derived 
neurotrophic factor; NRTN, neurturin; VIP, vasoactive intestinal peptide; PSARL, presenilins-
associated rhomboid-like protein; PEBP, phosphatidylethanolamine binding protein; ANP, atrial 
natriuretic peptide; MIF, Migration inhibitory factor. 
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Table 5.6. Sequence tags created via de novo sequencing with LC-ESI-IT MS/MS data.  
m/z z M.W. Sequence Tag 
622.7 2 1243.4 IDAV 
703.6 2 1405.2 EGD 
778.0 2 1554.0 VNA 
792.3 2 1582.5 SIC 
838.9 2 1675.8 YTGRV 
857.3 2 1712.6 CNFF 
857.3 2 1712.6 HRFI 
859.5 2 1717.1 TASHM 
868.5 2 1735.0 TIE 
868.6 2 1735.2 DTNT 
869.5 2 1736.9 NQFP 
890.5 2 1779.1 SAVI 
940.6 2 1879.2 PCA 
954.8 2 1907.6 TYT 
1005.4 2 2008.9 AIF 
1014.9 2 2027.8 DIYV 
412.1 2 822.2 PAT 
504.2 2 1006.4 CTC 
518.6 2 1035.2 AVVA 
530.5 3 1588.5 VVC 
540.0 2 1078.0 PIH 
552.7 2 1103.4 MVYEGQ 
566.4 2 1130.8 FPPI 
566.7 1 565.7 III 
575.9 2 1149.8 AVR 
601.2 3 1800.6 ACPP 
601.2 3 1800.6 YPP 
604.2 2 1206.4 IVS 
604.2 2 1206.4 IVC 
606.6 1 605.6 VII 
630.0 2 1258.0 PCPV 
630.0 2 1258.0 VVD 
630.0 2 1258.0 AEPV 
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Table 5.6 (cont.) 
m/z z M.W. Sequence Tag 
635.1 2 1268.2 DAFA 
635.1 2 1268.2 VAD 
645.9 2 1289.8 DNGVCNP 
649.5 2 1297.0 RSRPD 
650.5 2 1299.0 DQDE 
650.5 2 1299.0 DQDF 
674.5 2 1347.0 SSAVI 
697.6 2 1393.2 HIRPQ 
697.6 2 1393.2 TQN 
697.6 2 1393.2 EDE 
721.4 1 720.4 FDVIF 
747.8 2 1493.6 DDP 
794.1 2 1586.2 GCVYTA 
805.2 2 1608.4 GPIDD 
849.1 2 1696.2 NEW 
887.9 2 1773.8 INSAVI 
888.9 2 1775.8 YINSAVI 
890.2 2 1778.4 INSAVI  
900.4 2 1798.8 DINSI 
919.7 2 1837.4 INSAVI 
931.3 2 1860.6 MVDI 
1034.8 2 2067.6 TNTPVI 
1
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Table 5.8. Peptides released from astrocytes analyzed with LC-MALDI-TOF/TOF tandem MS. 
MH
+
obs. Acquisition Date mmddyy_Stimulus_Concentration_(Sample Spot) 
814.68 062207_BK_1mM_ (L), 062207_BK_100uM_ (K) 
885.01  062207_BK_100uM_ (K) 
910.59 102407_BK_1uM_1_(C) 
913.78 062207_BK_1mM_ (L) 
920.76 062207_BK_100uM_ (K) 
951.82 062207_BK_100uM_ (K) 
961.87 062207_BK_1mM_ (L) 
962.04 062207_BK_100uM_ (K) 
994.65 102407_BK_1uM_1_(C) 
1008.60 062207_BK_1mM_ (L) 
1015.80 062207_BK_1mM_ (L), 062207_BK_100uM_ (K) 
1024.15 062207_BK_1mM_ (L) 
1045.68 102407_BK_1uM_1_(C), 062207_BK_1mM_ (L) 
1050.11 062207_BK_100uM_ (K) 
1072.76* 091207_KCl_55mM_(J) 
1076.91 102407_BK_1uM_1_(C), 062207_BK_100uM_ (K), 062207_BK_1mM_ (L) 
1082.90 062207_BK_100uM_ (K), 062207_BK_1mM_ (L) 
1112.83 062207_BK_1mM_ (L) 
1117.66 102407_BK_1uM_1_(C), 051607_ionomycin_5uM_(O), 062207_BK_1mM_ (L) 
1121.05 062207_BK_100uM_ (K) 
1122.81 102407_BK_1uM_1_(C), 062207_BK_1mM_ (L) 
1123.23 062207_BK_100uM_ (K) 
1137.28 062207_BK_1mM_ (L), 062207_BK_100uM_ (K) 
1147.99 062207_BK_1mM_ (L) 
1158.01 062207_BK_1mM_ (L) 
1161.97 062207_BK_1mM_ (L) 
1186.74 102407_BK_1uM_1_(C) 
1239.14 062207_BK_1mM_ (L) 
1245.01* 091207_KCl_55mM_(J) 
1311.96 062207_BK_1mM_ (L) 
1404.67 070607_KCl_55mM_(P) 
1555.86* 091207_KCl_55mM_(J) 
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Table 5.8 (cont.) 
MH
+
obs. Acquisition Date mmddyy_Stimulus_Concentration_(Sample Spot) 
1646.98 051607_ionomycin_5uM_(O) 
1647.95 051607_ionomycin_5uM_(O) 
1779.75* 091207_KCl_55mM_(J) 
1921.14* 091207_KCl_55mM_(J) 
1937.51 70607_KCl_55mM_(P) 
2015.09* 091207_KCl_55mM_(J) 
2031.03* 091207_KCl_55mM_(J) 
2191.78 062207_BK_100uM_ (K) 
2192.41 070607_KCl_55mM_(P), 062207_BK_1mM_ (L) 
 
*, primary cultured astrocytes from rat hippocampus; if not labeled, astrocyte cell line cultures 
from mouse cerebellum. 
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6.2 Introduction 
Mass spectrometry (MS) has been successfully applied to characterize neuropeptides in a 
wide range of animals from invertebrates to vertebrates.
1-9
 The most common ion dissociation in 
the tandem MS for peptide identification is through energetic collisions with a neutral target gas, 
which is referred to as collision-induced dissociation (CID). As stated in Chapter 1, the structural 
information from CID of a peptide ion highly depends on the peptide itself. However, collision 
conditions such as the relative translational energy and the number of collisions also play a role 
in CID MS/MS results. These key experimental parameters in the CID of peptide or protein ions 
have been well studied, which provides a guide line to optimize the experiments for high quality 
tandem MS results.
10-13
  
Global peptide identification is generally accomplished by searching tandem MS results 
against the available protein or neuropeptide precursor databases. Several criteria such as mass 
accuracy tolerance and variable post-translational modifications are used in order to find the 
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most likely match. The commonly used database search engines are Mascot
14,15
 and 
SEQUEST.
16
 One problem associated with these programs is the short peptides versus the much 
longer proteins. For example, the minimum effective peptide length for searching in Mascot is 
larger than 5 amino acids. Although several de novo sequencing programs such as PEAKS,
17
 
PepNovo,
18
, and Lutefisk 
19
 are available, analysis of short peptides is challenging in current 
proteomics because of the limited fragmentation data.  
A computational model will be built for small peptide identification. High-quality tandem 
mass spectra of small peptides are important to train the new programs. Therefore, LC-MS 
analysis was optimized for producing tandem MS of 5-mer synthetic peptides. The importance of 
LC separation and MS high mass accuracy and resolution for small peptide identification in the 
complicated samples is illustrated below.  
6.3 Experimental 
 Three libraries of 5-mer synthetic peptides were obtained from Dr. Vivian Hook research 
group at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California, 
San Diego. The composition of the peptides is shown in Table 6.1. The libraries of peptides were 
dissolved into 0.1% FA aqueous solutions, and 0.5 g peptides in each library was analyzed by 
Ultimate
TM
 3000 NanoLC system (Dionex, Sunnyvale, CA) coupled to maXis
TM
 UHR-TOF MS 
system (Bruker Daltonics, Bremen, Germany). The MS was tuned and calibrated with ES 
calibrate solution (Sigma-Aldrich, St. Louis, MO), and the collision energy in MS/MS for small 
peptides was optimized with bradykinin (1-7) at m/z 757.3997 (Bruker Daltonics, Bremen, 
Germany) and HPLC peptide mix (Sigma-Aldrich, St. Louis, MO) including peptides Val-Tyr-
Val at m/z 380.2185, Leu-enkephalin at m/z 556.2766, and Met-enkephalin at m/z 574.6611. 
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The aqueous solutions of small peptides were picked up with an autosampler, and loaded 
onto a nano-HPLC column (Acclaim PepMap100, C18, 3 μm particle size, 100 Å pores, 75 μm 
i.d. × 15 cm, Dionex, Bannockburn, IL) for separation at a flow rate of 300 nL/min with solvent 
A (0.1% FA aqueous solution) and B (ACN/H2O, 80/20, v/v, with 0.1% FA). A gradient 
developed from 0% to 20% solvent B in 4 min, went up to 60% B in another 56 min, stayed at 
60% B for 12 min, kept going to 100% B in 15 min, stayed at 100% B for 10 min, and ramped 
back to 0% B in 1 min and maintained at 0% B until the 2-hr run finished. The elute was directly 
analysed by maXis
TM
 UHR-TOF MS (Bruker Daltonics, Bremen, Germany) in the mass range of 
50-1200 m/z with online nano-electrospray ionization source. Data dependent tandem MS was 
conducted with dynamic exclusion. DataAnalysis software (Bruker Daltonics, Bremen, 
Germany) was employed to display the MS and MS/MS spectra after automatic deconvolution. 
BioTools and Sequence Editor (Bruker Daltonics, Bremen, Germany) were used to assist the 
investigation of tandem MS of peptide standards and 5-mer synthetic peptides.  
6.4 Results and Discussions 
6.4.1 Small Peptide Detection with High Resolution LC-MS 
Decent tandem MS spectra showing full amino acid coverage of peptides are essential to 
train a computational model for peptide identification. Based on synthesis of 5-mer peptides with 
5 possibilities of different amino acids in each amino acid position, there are theoretically 3125 
(5
5
) peptides in different concentrations in each library. Therefore, a high-throughput technique 
is required to analyze as many peptides as possible in an LC-MS experiment. In addition, mass 
accuracy and mass resolving power are keys to obtained decent tandem MS for unbiased peptide 
identification. Firstly, the 5-mer peptides are not present in equal amount, and dynamic range 
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could be large. Therefore, a reasonable long gradient of LC mobile phases was developed as 
described above. Secondly, the composition of the peptides is heterogeneous with various amino 
acids, which caused the presence of both highly hydrophobic (e.g. VFAYL in Library 2) and 
highly hydrophilic (e.g. DREHK in Library 2) peptides. Aqueous solution was therefore used to 
load the peptides on the column to minimize the loss of highly hydrophilic peptides, and organic 
mobile phase reached high enough in the gradient to make sure all the highly hydrophobic 
peptides were eluted from the column. Thirdly, since most of 5-mer peptides appeared to be 
singly charged with a few of double charged ions, a method tuned to low masses without 
activating the exclusion of singly charged ions for MS/MS was used, and the instrument was 
calibrated with the standards whose masses covered the masses of interest (m/z=400–900, z=1) 
within ppm to sub-ppm. The mass resolution reached 20–40k. Figure 6.1 shows the MS spectrum 
of peptide standards, and the insert is zoom-in spectrum of singly charged Leu-enkephalin. 
6.4.2 Small Peptide Fragmentation  
Because small peptides have relatively simpler 3-D structures, and they are easier to be 
fragmented compared to larger peptides, lower collision energy was applied to get the amino 
acid residues. The available collision energy for general peptidomics is shown in Table 6.2. With 
the general collision energy table, Leu-enkephalin was fragmented too much, only showing the 
smaller fragments in mass range of 100-200 Da (Figure 6.2 top). With the optimized lower 
collision energy shown in Table 6.3, better amino acid coverage of Leu-enkephalin in tandem 
MS was obtained (Figure 6.2 bottom). Sequencing Leu-enkephalin was conducted with the 
tandem MS under optimized condition in BioTools incorporated with Sequence Editor, as shown 
in Figure 6.3. Peptide VYV (m/z=380.2180, z=1) and bradykinin (1-7) (m/z=757.3997, z=1) were 
used to optimize the collision energy for masses between 300 and 700 Da (Figure 6.4). Our result 
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indicates that a list of optimized collision energy with lower values should be considered to add 
into the general collision energy table in order to improve the identification of small peptides in 
the complicated biological samples. 
6.4.3 Small Peptide Identification 
Mass accuracy is critical to differentiate the peptides of similar molecular weight with or 
without similar amino acid composition. The different elution time of these peptides also helps 
the correct assignment of the peptide identities. As shown in Figure 6.5, multiple possible 
sequences are present for the peptide at m/z about 546.26-546.32 (z=1) in Peptide Library 1. 
Extracting the ion chromatograms for masses at 546.26±0.02, and 546.32±0.02, two peaks eluted 
at about 35 min and 55 min were observed. Corresponding to these two ion chromatogram peaks, 
two tandem MS spectra were obtained at m/z 546.2657 and 546.3312, respectively. Matching the 
possible sequences with the tandem MS spectra within 100 ppm, the assignment of these two 
peptides with sequences LEGPM and LALVM was accomplished (Figure 6.6). Given the 
hydrophobicity of the peptides, the assignments also match the elution order of the two peptides. 
Peptide LALVM consists of multiple highly hydrophobic amino acids, and was eluted in higher 
organic mobile phase than peptide LEGPM.  
6.5 Conclusions 
In summary, both optimized LC separation and MS detection play an important role for 
peptide sequencing and identification. The loading solution should be appropriately selected for 
reducing the peptide loss prior to the separation. A gradient should be developed to resolve as 
many peptides as possible, facilitating the MS detection. Collision energy should be optimized 
for the masses covering the peptides of interest to produce entire amino acid fragments. High 
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mass resolution and mass accuracy are keys to differentiate the peptides with similar molecular 
weight. In addition, the predicted information from both LC separation based on peptide polarity 
and signature fragment ions produced by MS/MS based on their amino acid compositions should 
be used for correct peptide identification. 
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6.6 Figures 
 
 
 
 
 
 
Figure 6.1. Nano-electrospray ionization quadrupole time-of-flight tandem mass spectrum (nano-
ESI-Qq-TOF MS) of peptide standards. The insert is the zoom-in spectrum of Leu-enkephalin at 
m/z 556.2766, z = 1. The different peaks in the insert show the isotopic distribution of Leu-
enkephalin. 
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Figure 6.2. Nano-electrospray ionization quadrupole time-of-flight tandem mass spectra (nano-
ESI-Qq-TOF MS/MS) of Leu-enkephalin (m/z = 556.2766, z = 1) acquired with a collision 
energy table for general peptidmocis study (top) and optimized for small peptide sequencing 
(bottom). 
 
 
 
 
Figure 6.3. Sequencing of Leu-enkephalin (m/z = 556.2766, z = 1, sequence: YGGFL) using 
nano-electrospray ionization quadrupole time-of-flight tandem mass spectra (nano-ESI-Qq-TOF 
MS/MS) with optimized collision energy. The assignment of b-, y-, and internal fragment ions 
matches expected fragments within 100 ppm. 
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(A) 
 
(B) 
 
 
Figure 6.4. Sequencing of small standard peptides (A). VYV (m/z = 380.2180, z = 1) and (B). 
Bradykinin (1-7) (m/z = 757.3997, z = 1, sequence: RPPGFSP) using nano-electrospray 
ionization quadrupole time-of-flight tandem mass spectra (nano-ESI-Qq-TOF MS/MS) with 
optimized collision energy. The assignment of b-, y-, and internal fragment ions matches 
expected fragments within 60 ppm and 70 ppm, respectively. 
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Figure 6.5. Identification of 5-mer peptides with nano-LC coupled to nano-electrospray 
ionization quadrupole time-of-flight tandem mass spectra (nano-LC-nano-ESI-Qq-TOF MS/MS) 
with optimized collision energy. On the left list the possible peptide sequences in the peptide 
library with similar or the same masses. On the right top are the base peak chromatograms 
indicating two peptides with masses 546.26±0.02 and 546.32±0.02. On the right bottom are the 
tandem mass spectra corresponding to the base peak chromatograms with m/z = 546.2657 and 
m/z = 546.3312 (z = 1). 
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(A) 
 
(B) 
 
 
Figure 6.6. Assignments of the tandem mass spectra in Figure 6.5 with peptide sequences in the 
peptide library. The tandem mass spectrum at m/z = 546.2657 (z = 1) is assigned to LEGPM with 
MS tolerance of 11 ppm and MS/MS tolerance of 100 ppm, and the one at m/z = 546.3312 (z = 
1) is assigned to LALVM with MS tolerance of 2 ppm and MS/MS tolerance of 100 ppm. 
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6.7 Tables 
Table 6.1. The composition of the three 5-mer peptide libraries. Each amino acid (A.A.) position 
could be occupied by one of the five amino acids listed in the table. In theory, the number of 
total synthetic peptides is 3125 (5
5
) in each library.  
 A.A. 1 A.A.2 A.A.3 A.A.4 A.A.5 
Library 1 MEWTL GDAFE SLRGN VPQHF MAYKR 
Library 2 QDSVF FARGN VAETM YPGHL EWLKR 
Library 3 HYGNA SDGFM QVNLT RAPLM DEWKR 
 
 
Table 6.2. Collision energy table used for general peptidomics (m/z = 50-3000). 
Isolated Mass Isolated Width Collision Energy Charge State 
500 8 35 1 
500 8 25 2 
500 8 20 3 
1000 10 50 1 
1000 10 40 2 
1000 10 35 3 
2000 15 70 1 
2000 15 50 2 
2000 15 45 3 
 
 
Table 6.3. Collision energy table optimized for 5-mer peptide fragmentation (m/z = 50-1200). 
Isolated Mass Isolated Width Collision Energy Charge State 
300 8 15 1 
500 8 15 1 
700 8 35 1 
1000 10 50 1 
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